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PART 1. BACKGROUND
Introduction
Diane E. Meier, MD
diane.meier@mssm.edu
Striking gains in life expectancy—for example from an average of 50 years in
1900 to 78 years in the United States today—have transformed human
experience across the globe. Health care needs have followed suit. At the turn
of the last century, most deaths followed an acute infectious illness afflicting
young and old alike; today most deaths occur in older adults, following years of
chronic illness. This trend toward chronic illness has been universally observed,
but despite the prevalence and impact of this trend, the health care systems of
the world have not kept pace. In the United States, for example, the health care
system is structured around easy access to acute hospital care and does not
support the community-based coordinated care required by the chronically ill. A
growing body of evidence demonstrates high levels of suffering, dissatisfaction
with, and overuse of health care resulting from the mismatch of patient and
family needs with the health care system as it is currently structured. As a
response to this trend, the new specialty of palliative medicine has grown
rapidly in the last 10 years, winning American Board of Medical Specialties
subspecialty status in 2006.
Palliative medicine is medical care focused on relief of physical, emotional, and
existential suffering, and support for best possible quality of life for patients and
their family caregivers. It is delivered at the same time as all other appropriate
(i.e., likely to benefit the patient) medical care and should be offered simultane-
ously with curative, life-prolonging, or disease-modifying treatments. In practice,
palliative care involves assessment and relief of troubling symptoms as well as
skilled communication with patients and families about the goals of care and the
treatment plan that will achieve these goals and attention to safe and well-
coordinated care across the multiple settings that patients traverse during
serious illness. Palliative approaches to care are a core responsibility of
clinicians from all specialties, with expert consultation sought for intractable or
especially complex problems.
This review from the BMJ Group synthesizes the evidence supporting key
elements of palliative care: the control of common symptoms such as pain,
dyspnea, and fatigue; communication and goal setting; and effective, efficient
transition management. Following the synthesis of the best evidence are 4
Toolkits containing tools and technical assistance to support the busy clinician
seeking rapid access to best clinical practices. We hope that these resources
will help physicians as they seek to “Cure sometimes, relieve often, comfort
always” (14th-century French proverb).
Demographics and disease burden
During the past century, progress in clinical medicine, public health and living
standards has resulted in enhanced quality of life and a longer life expectancy
for many.1
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In 2007, average life expectancy in the U.S. was estimated to be 75 years for
men and 81 years for women.2 Currently, around 12% of the U.S. population is
older than 65 years of age, with the aging of the baby boomer generation
expected to increase this percentage to 20% by 2030.1,3 Cause of death is now
much less likely to reflect acute illness such as infectious diseases or trauma,
and more likely to be due to the impact of chronic disease. As individuals age,
their risk for disability rises; after the age of 85 years, 95% of individuals have
reduced mobility and 50% suffer from memory loss secondary to dementia.
Ninety percent of senior Medicare enrollees live with at least one of these
illnesses in the year prior to death. As a consequence many people experience
“end of life” not as a brief illness but as a prolonged period of months or years,
during which they are treated for and have to cope with deterioration of their
physical and mental functions.
Between 2004 and 2006, U.S. hospital costs rose by nearly 20%, primarily
because of the larger numbers of patients seeking care in hospitals, and the
increase in availability of costly life-sustaining interventions.1 Hospitals now
receive 75 cents of every Medicare dollar.4 The medical costs incurred during
the last years of life are high; over 50% of lifetime medical expenses occur after
the age of 65, and 33% after 85 years of age. In the last year of life, an
individual incurs about 30% of his or her lifetime Medicare expenditures.
However, spending on palliative and hospice interventions accounts for a small
percentage of this. Moreover, palliative medicine has been relatively neglected
in the U.S. undergraduate curriculum, although this appears to be changing. A
systematic review (search date 2006) found a considerable increase in the
provision of palliative care training in U.S. medical schools between 1999 and
2006, and by 2005 there were 52 fellowships in hospice and palliative
medicine.5
The care of patients with advanced illness is hindered by undertreatment of
physical and emotional symptoms, psychological and physical debilitation of
caregivers, conflicts over decision making, and diminution of family financial
resources.3 Patients often receive care that lacks continuity, with multiple care
settings, multiple providers, confusing payment systems, and lack of critical
services such as home and caregiver support.
Definitions
Palliative care has its roots in the hospice movement, which began in the 1960s
in the U.K. and in the 1970s in the U.S.4 It aims to relieve the suffering and
improve the quality of life for patients and their families with advanced disease.
In 1983, U.S. federal legislation created the Medicare Hospice Benefit, which
has since provided palliative care services to more than 7 million terminally ill
patients, usually within their homes. However, palliative care services can assist
many patients with advanced chronic diseases who are not eligible for hospice
benefits. In too many cases, comfort care measures are only introduced when
death is imminent. This situation is exacerbated by the current structure of the
U.S. health care reimbursement system with its two-tiered funding for curative
2 © BMJ Publishing Group 2008
therapies (regular Medicare funds) and comfort care (Medicare Hospice
Benefit).3 Under current regulatory and compensatory Medicare Part A rules,
patients are eligible for hospice if their physician states that death is likely within
6 months, and the patient is willing to shift the focus of care to “palliative care”,
which for reasons related to the funding stream to hospice agencies, means the
patient must forego attempts at curative or life-prolonging treatments. The goal
of this program is to enable families to care for their loved one at their home,
with a focus on control of distressing physical and psychological symptoms and
spiritual concerns.4
A systematic review (search date 2004) found that hospice utilization is on the
rise in the U.S.; about 20% of patients now receive hospice care.6 However,
patients were being referred for hospice care at later phases in their diseases.
The median length of time in hospice dropped from 29 days in 1995 to its
lowest level (20.5 days) in 2001, and was at 23 days in 2003. In 37% of cases,
death occurred within a week of the patient’s enrollment. The review recom-
mended hospice enrollment to lower hospitalization mortality rates, curtail the
transfer to the hospital of dying nursing facility patients, and ameliorate
suffering.
The WHO’s definition of palliative care includes relief of suffering, enhanced
quality of life, and support for patients and families. It enumerates the following
goals and principles:7
+ To regard death as part of life and a normal process
+ Neither to hasten nor to delay death
+ To use a team approach to address the needs of patients and their families,
including bereavement
+ To initiate palliative care early in a patient’s illness, even when he or she is
still receiving life-prolonging treatments such as chemotherapy or radiation
therapy.
Hospitals are increasingly investing in palliative care services to improve patient
care, enhance patient satisfaction, and reduce ICU and total bed days and
costs.4 In 2003, over 25% of U.S. hospitals had a palliative care program.8
Overall, these programs have been found to be effective in facilitating patient
transitions from acute, high-cost hospitals to more suitable settings, such as the
home.4
Illness trajectories
Three disease trajectories can be used for categorizing most patients with
advanced chronic illness, including:9
+ Progressive disability and eventual death over a period of weeks or a few
months, most often seen in patients with the most common solid malignances:
accounting for about 20% of deaths over the age of 65 years
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+ Slow decline with acute exacerbations and often a sudden death, most often
due to chronic organ failure (e.g., lung, kidney or heart failure): about 25% of
deaths over the age of 65 years
+ Long period of slow decline with worsening self-care ability; death often from
an unpredictable intercurrent illness; the underlying condition is typically a
chronic neurodegenerative disease such as dementia: about 40% of deaths
over the age of 65 years1,10
Prognostic accuracy
Physicians’ survival predictions are often inaccurate; in particular, they tend to
be overoptimistic. A meta-analysis (search date 2000) of 8 studies in terminally
ill cancer patients showed that median clinical prediction of survival (CPS) was
42 days, whereas median actual survival (AS) was 29 days.11 Only 61% of
expected survival estimates were accurate to within 4 weeks. Another review
(search date 2006) identified a survey study in 258 physicians managing 300
cancer patients admitted to outpatient hospice programs and reported lengths
of median “physician-communicated” survival prediction of 90 days, median
“privately formulated” survival prediction of 75 days and median “actual” patient
survival of 26 days.12 Despite this, CPS and AS were strongly correlated (P less
than 0.001) and studies have shown CPS to be a better prognostic factor than
conventional tools such as performance status and symptoms and that it
increases in accuracy in patients who are closer to death. A number of reasons
may be responsible for clinician’s over-optimism. Predicting the expected range
of time in which death is likely to occur is a difficult skill to master.13 A
long-standing patient-doctor relationship may also influence their ability to
prognosticate. The study noted that those who had not known the patient for
long prior to the assessment scored better. Besides, physicians may want to
preserve patients’ hope.14 Whereas oncologists seem to be in favor of providing
prognostic information to patients with early stage disease, they find it more
difficult to communicate prognosis and are less willing to give specific estimates
of survival to patients with advanced cancer even if requested.15
Prognosis discussions with patients need to convey that uncertainty about the
course of illness in individuals is to be expected. Although clinicians need to
allow that patients are more likely to assume they are among those with the
best prognosis.16
A review concluded that there was still further need for the systematic
development of prognostic scales.16 Studies including more than 1000
advanced cancer patients found the Palliative Prognostic Score (PaP) to be the
best validated, simple, quick and commonly used indicator.17 Its variables
include dyspnea, anorexia, Karnofsky performance status, clinician prediction
of survival (in weeks), total WBC count and lymphocyte percentage. It has been
used to categorize patients with advanced cancer into 3 distinct prognostic
groups (30-day survival probability: less than 30%, more than 70% or in
between) and to offer quantitative guidance on the appropriateness of immedi-
ate referral into palliative care programs for this population.16
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Figure 1. Typical illness trajectories for people with progressive chronic
illness.[BMJ]
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Other validated palliative prognostic scales in advanced cancer included were
the palliative prognostic index (PPI), Chuang prognostic scale, terminal cancer
prognostic score (TCP), and Bruera’s poor prognostic indicator. All scales were
found to have limitations, but were significant improvements on any unadjusted
clinician estimates.
Prognostication in nonmalignant disease can be even more difficult. A system-
atic review of 11 primarily prospective cohort and longitudinal studies sug-
gested the lack of reliable prognostic models for this patient group contributed
to the unfilled need for palliative care services for older patients with nonmalig-
nant, life-threatening diseases.18 The review identified generic predictors of
survival for this population: increased dependency in activities of daily living,
comorbidities, nutritional status and weight loss, and abnormal vital signs and
laboratory tests. Although disease-specific predictors of survival are available
further research is needed.
What patients know and what they want to know on
prognosis
Both patients and caregivers require more information than is offered and there
is a large discrepancy between patients/caregivers and health providers on the
amount of information they believed had been given.19 Most patients want
accurate and detailed prognostic information, although a minority does not. In
the SUPPORT study20 around 1 in 5 would rather not discuss end-of-life
options.21 Therefore the clinician needs to plan how to elicit these patients’
general preferences and designate an appropriate proxy. Even clinicians who
believe they should disclose terminal diagnosis often fail to initiate discussion.
Most patients prefer their physician to raise the subject.22,15 Two studies
identified by a systematic review found that many patients preferred their
physician to ask them first if they wished to know their prognosis and in what
detail.
Studies have identified cultural differences in expectation around provision of
prognostic information.16 Whereas most white and African American patients
expect to be provided with full information to make informed decisions, in some
other cultures (e.g., Asian, Navajo, African, Central and South American and
Eastern European cultures), nondisclosure of bad news or use of nonverbal
means is expected. However, preferences vary and assumptions based on
ethnic background can be misleading, so prior discussions on appropriate
levels of information are always indicated.
Patients’ care needs and preferences during advanced
illness
Patients’ values and preferences should guide life-sustaining care but observa-
tional studies report lack of knowledge of individual patients’ preferences by
physicians/caregivers.23 Early consideration of preferences increases the likeli-
hood that care will be consistent with these later on.
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Physicians can help patients with life-threatening diseases to identify their
needs and preferences for care, and examine areas of doubt or conflict around
these preferences. One review identified the following 3 domains of patient
perspective that influence preferences for care: feelings about their disease,
level of suffering, and circumstances of death.24 In discussing these issues,
physicians need to take into account that patients vary in their interest in curing,
modifying or monitoring their underlying disease. Patients’ perceived level of
suffering is dependent upon the quality of symptom control, available emotional
support and overall quality of life. Preferences regarding the circumstances of
death may include decisions on when to limit or withdraw interventions, where
to die and the desire to hasten death. By assessing these domains, the care
team can guide and assist with the development of a patient-centered plan of
care.
Another systematic review identified 11 qualitative studies exploring spirituality
from the perspective of patients. It found spiritual concerns to be centered on
three main themes: a sense of spiritual/existential despair, with associated
feelings of alienation, loss of self, and uselessness; spiritual work such as
forgiveness, self-exploration, reconciliation, and acceptance; and the sense of
spiritual well-being, demonstrated by feelings and thoughts of wholeness,
connection, and satisfaction.25
The U.S. Patient Self Determination Act of 1991 confirmed that patients have
the right to refuse life-sustaining treatments. The law also requires health care
facilities/agencies to discuss and provide assistance in the completion of
advance care planning documents.26 State-specific documents and detailed
guidance are available at http://www.caringinfo.org.When patients are unable to
make their own medical decisions (’incapacity’), depending on the state, either
a patient-appointed surrogate decision maker, or next-of-kin surrogates are
authorized to make decisions. Both types of surrogates predict patients’
treatment preferences in about 68% of cases.27 Most patients expect their
family to play a role in making decisions and a review found moderate evidence
from 3 RCTs that interventions aimed at surrogates or patients improved
understanding of wishes.8 Another review identified found 3 further RCTs,
which provided low-quality evidence that a facilitated discussion with terminally
ill patients and their surrogates may result in patients being less likely to
undergo life-sustaining treatment.28
One systematic review (search date 2003) of mainly small, nonrandomized and
uncontrolled studies found that African American people were more likely to
request life-sustaining therapies at the end of life than white people, and less
likely to seek physician-assisted suicide or adopt advance care planning.29
Strong spiritual beliefs and regular attendance at prayer activities in other ethnic
groups were also associated with these care preferences.
Site of death
Recent surveys have shown that most cancer patients in the U.S. express a
preference to die at home.30,31 Despite this, about 75% of Americans with
7© BMJ Publishing Group 2008
chronic illnesses die in a hospital or nursing home setting, although there are
large regional differences.32 Between 1989 and 2001 the overall rate of home
deaths increased (from 16% to 23%), hospital deaths decreased (from 62% to
nearly 50%) and the likelihood of dying in nursing homes rose from 19% to
23%.33 A systematic review (search date 2003, 66 observational studies)
identified a multitude of factors influencing the location of death for people with
chronic diseases.32 These included clinical considerations, individual and
community-based sociodemographic characteristics, the availability of health
care resources, and local reimbursement policies. It found that being white,
native-born, married, of higher socioeconomic status, and living farther away
from a university health center is associated with home death, whereas being
black, Latino or other nonwhite increased likelihood of hospital death.
A systematic review (search date 2004) including 58 studies and totaling over
1.5 million patients from 13 countries, primarily the U.S., U.K., Australia and
Canada, evaluated the influence of different factors on location of death for
cancer patients.34 It identified 6 factors associated with home death location:
low functional status, a stated desire for home death, a shared living arrange-
ment with family, the support of an extended family, home care and its
frequency. Another systematic review (search date 2003) reported that cancer
patients more frequently died at home compared with other causes of death.32
Measures of hospital use intensity (number of hospital beds, average hospital
length of stay, hospital days per capita) were positively associated with
increased hospital death, and age, gender, and caregiver ability and availability
were also likely to play a part. The U.S.-based SUPPORT study showed
hospital bed capacity to be the strongest predictor of hospital death: the larger
the number of available hospital beds in a community, the more likely the patient
was to die in hospital.35 This study found little or no impact on location of death
from patient and family preferences, physician preference, and advance care
planning.
Desire to die requests
One systematic review (search date 2005) in people with terminal cancer found
that many desire-to-die requests were expressions of psychological distress.36
Among those specifically seeking information or assistance with hastened
death, the main reasons were fear around being a burden, loss of dignity and
independence, and unrelieved pain. The review recommended psychosocial
interventions, psychiatric care for patients wishing to die, and better training for
clinicians. Unfortunately obtaining psychiatric care for patients with highly
advanced disease can be extremely difficult.
Patient–caregiver relationship
Primary lay caregivers, often the patient’s spouse, frequently play a major role
in the home care of patients with cancer, dementia, strokes and AIDS,
particularly in advanced stages.37 A systematic review (search date 2004)
reported that surveys indicate that 20% of caregivers provide full-time or
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24-hour care, 20% quit their regular positions or sustain other major life
transitions, and 31% lose significant portions of or even all their savings.6
Social pressure can mean that those who feel unable to care effectively may be
reluctant to indicate this. Lack of skills, limited functional capacity, additional
family or employment responsibilities, and the symptom burden may all restrict
the ability to provide care. The quality of the patient-caregiver relationship is a
major predictor of willingness to care. Having had the opportunity to adjust
gradually to the caregiving role increases the likelihood of caregivers to
continue providing care in the event of a crisis, although caregiving refusal can
occur at any point.37
The perception of not having a choice and reports of being stressed are
associated with impaired health outcomes among caregivers. Prospective
cohort studies have demonstrated adverse effects on the emotional health of
the caregiver including depression and anxiety.38 Cohort studies have also
identified increases in physical stress and even mortality among caregivers.39
Psychosocial care is important for the patient and family. This goes beyond the
psychological symptoms of the patient to helping the entire family to cope.
Increasing numbers of interventions designed to improve the well-being of
caregivers are being developed but most have not been adequately studied.40
Most caregiver interventions are focused on decreasing the work load or
improving coping skills without addressing the added stress of watching a loved
one suffer.41 Additional research is needed but many experts recommend
screening caregivers for stress, with a focus on those who feel trapped.
Higher caregiver stress levels are associated with an increase in the patient’s
symptoms.6 If people are pressured into a caring role this is associated with
worse clinical outcomes in patients, more frequent institutionalization, and
reduced quality of care.37 A further review found that elderly patients nearing
the end of life are at heightened risk for abuse, resulting from caregiver stress,
patients’ dependency, and weak social support networks.42 Abuse can be
physical, emotional, sexual or financial. Neglect was identified as the most
common type of elder victimization at the end of life. The overwhelming majority
of abuse occurs in the home and is committed most commonly by the patient’s
spouse (58%) or child (47%), irrespective of socioeconomic status and ethnic
background. Ready availability of professional care services such as multidisci-
plinary palliative or hospice care teams can be used to assess the potential for,
and hopefully prevent, abuse, although high-quality evidence is lacking.
For many patients nearing the end of life, their self-perceived burden to others
is a major concern. A review (search date 2005) suggested self-perceived
burden was associated with anxieties over dependency, hopelessness, guilt,
loss of dignity and control, and of having a “bad death”.43 In some cases, it
might motivate the patient to decline life-sustaining treatments, even spark a
desire for a hastened death.
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Barriers to delivering effective palliative care
Despite an increased understanding of the factors necessary for optimal
palliative care, there are numerous obstacles. We provide an overview of these
building on a conceptual framework in a systematic review (search date 2002)
of end-of-life cancer care.44
1. Societal attitudes
+ Mass media portrayal of the end-of-life period: Focus on physician-assisted
suicide and stories of individual cancer patients may instill fear of a painful
death, reduce expectations for quality of life, and prevent pursuit of adequate
quality of life in the course of illness. Media focus on relatively unusual cases
provides a skewed picture of typical end-of-life scenarios.
+ Technological advances and increases in hospitalization: These factors may
lead patients and their families to assume that intensive medical intervention is
appropriate in all situations.
2. Health care system
+ Rapid changes in the health care delivery system: Increased medical
spending and resulting cost containment efforts have led to competition
between health plans to attract healthy patients, and reduced insurance
benefits and innovation in chronic disease and palliative care. The reimburse-
ment climate has also put physicians under increased time pressures to
increase patient encounters resulting in less time for patients’ psychosocial and
spiritual issues.45
+ Limited availability of palliative care services: Hospice care is available for
patients with a prognosis of 6 months or less who are willing to give up
insurance coverage for curative or life-prolonging treatments. Patients whose
prognosis is indeterminate or those who wish to pursue life-prolonging thera-
pies are ineligible for hospice services. Nonhospice palliative care is available at
an increasing number of U.S. hospitals, but remains difficult to access in nursing
homes and community settings.
+ Medicare organization: Over 80% of hospice care in the U.S. is provided
through Medicare. Medicare regulations inhibit use of the skilled nursing benefit
combined hospice care.
+ Fragmented coverage by insurers at the end of life: Content and coverage of
coverage varies widely between insurers and figuring out eligibility for an
individual patient can be complicated and time-consuming for health care
providers. Outside managed care, services not covered by insurers (including
most prescription medications such as oral analgesics), co-pays and deducti-
bles may all lead to financial barriers.
+ Increased reliance on informal caregiving: Due to fragmented care and
shorter lengths of hospital stay, family members and friends may need to
provide complex care without formal training, which can lead to physical,
financial and emotional stress, and suboptimal care.
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+ Regulatory restrictions: Although state laws regulate prescribing opioids
(including dosages and complicated prescribing requirements) in terminal
illness in most states, the regulatory requirements for the care of terminal
patients are not as big a barrier as they are perceived to be. Information on
state pain policies is provided at http://www.painpolicy.wisc.edu/states.htm.
+ Off-label prescription: With some newer drugs, “off-label” reimbursement by
third-party payer (insurance) may be an issue.
3. Health care provider
+ Poor communication with patients and families, and between providers:
Physicians are typically reluctant, lack the requisite time, or are poorly prepared
to communicate with patients and their families. Health care providers may fail
to transmit information about patient preferences to each other.
+ Underreferral to palliative care specialists or services: In addition to unreal-
istic prognostication and patient desire for life-sustaining treatments, delay in
palliative care referral may be due to physicians’ lack of knowledge about
palliative care or hospice, or their services, discomfort with the subject, and
service availability.
+ Limited ability to recognize and appropriately treat common symptoms:
Providers often undertreat pain due to physician–patient discrepancy in the
rating of patient pain. A systematic review (search date 2006) identified further
physician-related barriers to pain management with opioids in cancer patients.46
These included concerns about side effects, underdosing, and inadequate
treatment of side effects from opioids. Physicians may fail to detect psychologi-
cal distress, anxiety and depression, or to distinguish associated symptoms
from side effects of treatment.
+ Lack of training in palliative care: Formal palliative care training in medical
schools, residencies and fellowships remains poorly coordinated and of variable
quality.
4. Patient and family
+ Patient’s ability to confront death: Fear and unwillingness to accept progno-
sis can lead to lack of acceptance of terminal disease.47
+ Patient’s attitudes toward the sick role: Some patients may feel the need to
be stoic leading to undertreatment of pain, nausea and depression; others may
underreport symptoms for fear of hospitalization, or because of fear of distract-
ing the physician from curative or life-prolonging efforts.
+ Patient’s attitudes toward palliative treatments: A systematic review (search
date 2006) identified patient-related barriers to appropriate management with
opioids in cancer patients.46 Patients may see morphine as comfort for dying
patients rather than a legitimate treatment for pain.48 Family members may not
realize that improved pain control can be achieved.49 Both patients and their
families have inaccurately inflated estimates of the risk of psychiatric addiction
from opioids analgesia.
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+ Inadequate or lack of insurance coverage: Real or perceived inadequacies of
insurance coverage may delay or prevent access to palliative care services.
+ Other factors: Men and patients in rural communities are slower to enroll in
hospice.50 Language and culture differences may lead to disparities in hospice
care access and use.51
Noncancer diagnoses
+ The role of palliative care in patients with chronic illnesses other than cancer
is often not recognized.52 For patients with heart failure, prognostication may be
especially difficult and doctors need to be better at integrating patient prefer-
ences into goals of care.21 In the SUPPORT study, only 25% of patients
hospitalized with heart failure recalled discussions with physicians about
resuscitation and 20% changed preferences after discharge.
+ Similarly, patients with advanced COPD often do not receive palliative care
services despite their poor prognosis, dyspnea, disability, anxiety and
depression.53 Only 32% of COPD patients report having had a discussion about
end-of-life care with their physician.54 One review indicated that only a minority
of patients with moderate to severe COPD have discussed treatment options
with their physicians.
+ Dementia is rarely viewed as a terminal illness, which means that patients
with dementia often receive inadequate or no palliative care and live and die in
pain.55
Communication
Good communication is essential to effective palliative care. Key skills for
clinicians include:
+ communicating bad news
+ conducting a goal setting meeting with patients and their families
+ discussing advance care planning including artificial nutrition and hydration
and DNR issues.
Few high-quality RCTs exist on the effectiveness of training to improve
communication skills or the effects of different communication approaches in
palliative care. Most recommendations and reviews are based on focus groups,
patient surveys and expert opinion.16
Good communication requires preparing for the encounter, creating a support-
ive environment, active listening, appropriate awareness of nonverbal behavior,
and expressing empathy.16 Clinician’s should be open to exploring emotion and
meaning.56 It is important to evaluate the patient and family’s knowledge of the
current situation and desire to learn new information about prognosis and what
the future holds, and to communicate in a manner appropriate to their culture
and education. Bad news may be followed by acceptance or denial and
appropriate strategies for both situations should be prepared.
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There is moderate-quality evidence that:
+ Intensive education improves clinician communication skills
+ Provision of prompt cards to patients improves communication.
Approximately 70% of family physicians who provide palliative care have no
training in communication skills.57 A systematic review (search date 2005) of
residents’ end-of-life decision-making with adult hospitalized patients identified
26 studies of mixed designs and found residents unprepared to handle patient
end-of-life decision-making.58 Another systematic review (search date 2005)
identified 18 low-quality, heterogeneous studies.57 These suggested some
benefit from a multifaceted, interactive approach to palliative care training for
primary care physicians, as opposed to traditional didactic teaching. A review
suggested that clinicians find discussions most difficult with elderly patients, but
there is little good evidence on improving those skills.59
A systematic review (search date 2001) identified one large RCT, which found
that training oncologists in communication during a intensive 3-day course
increased rates of focused questions (34% increase, P less than 0.005),
focused and open questions (27% increase, P = 0.005), expressions of
empathy (69% increase, P greater than 0.005) and appropriate cue responses
(38% increase, P less than 0.05) at follow-up.60 An additional RCT demon-
strated significant benefit from the provision of question prompt lists to patients
prior to consultation, which were then used by the physician during the
consultation.61 It found that patients asked significantly more questions (relative
risk [RR], 2.3; 95% CI, 1.7 to 3.2), discussed more end-of-life issues (30% vs.
10%; P = 0.001) and had longer consultations (average, 38 minutes vs. 32
minutes) with the intervention.
Evidence on interventions to increase utilization and
completion of advance directives
There is moderate-quality evidence that:
+ Multifaceted interventions increase completion of advance directives and the
likelihood of adherence to patient preferences
+ Providing a trained facilitator increases decisional competence
+ Forms designed for those with low literacy increase completion rates
+ Peer mentoring increases advance directive completion rates among African
Americans
Our literature search identified 3 systematic reviews and 3 subsequent RCTs on
advance care plans.8,62,63,64,65,66 The first review (search date 2007) found
moderate evidence that multicomponent interventions yielded more advance
directives than limited strategies.8 The second review (search date 2005)
identified 25 studies (both RCTs and observational) and reported that didactic
interventions (clinical mailings, education or information programs) did not
appear to increase uptake of advance directives, but interactive measures were
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more effective (23% to 71% increase in completion).62 This finding was
confirmed by a subsequent RCT (469 adults with psychiatric disorders) that
compared an opportunity to meet individually with a trained facilitator to create
a psychiatric advance directive vs. a control group receiving written materials
about advance directives.64 The third review (search date 2005) identified 18
RCTs and observational studies in primary care.63 It concluded that interven-
tions (mostly patient-directed interventions such as educational mailing, infor-
mation at visit, discussion with social worker, single-group lecture, or physician-
directed interventions such as group education of physicians or reminders to
discuss) increased take up of advance directives. However, results were poorly
reported and not broken down by kind of intervention. A second RCT found that
a redesigned form to meet the literacy level of most adults produced higher
acceptability (P = 0.03) and completed more advance directives.65 The third
RCT (297 people admitted to hospital) compared routine care vs. a scripted
intervention.66 It found 13% in treatment group advance directive completion
versus 1% in the control group (P less than 0.01).
Advance care planning
Although observational studies and expert opinion have indicated support for
advance care planning from patients, caregivers and physicians and desire of
patients to participate in decision-making, advance directives still have a low
prevalence even among at risk populations. The most cited reason by clinicians
is insufficient time, but another issue may be lack of reimbursement. Patients
should feel advance care planning is part of routine care and their values are
important for decision making.67 Completion of advance directives is a process
and there is a higher likelihood with repeated contact. The well-equipped office
should include state-approved advance directive forms and a checklist in the
patient chart to ensure that it is filled out. A team approach involving other
qualified health professionals is recommended. Once completed, they need to
be revisited regularly as patients’ preferences have been shown to change over
time. Plans should be revisited at diagnosis, following frequent hospitalizations
and on declining functional status. Many forms are insufficiently detailed and
poorly implemented. The goal should be genuine understanding, not just
completing a document. Observational studies have shown a lack of transmis-
sion of information about patient preferences between providers, a concern
considering the high rate of care transitions in late life. Two observational
studies found no evidence of benefit from portable health records.
There is a need to move from an exclusive focus on advance care directives to
a more comprehensive approach to advance care planning, with systems in
place that ensure the wishes of the patient are actually honored. All stakehold-
ers need to be aware of and involved in the plan. Advance care information
needs to be available to the right people, at the right time, with services
organized to provide the chosen level of medical intervention. One important
approach is the Physician Orders for Life-Sustaining Treatment (POLST) form
and program, and related programs Physician Orders for Scope of Treatment
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(POST) and Medical Orders for Life-Sustaining Treatment (MOLST).68 Informa-
tion about the program and sites across the U.S. are available at http://www.
ohsu.edu/polst/professionals.shtml. Key elements include: a protocol outlining
policies and procedures for transferring information about preferences across
health care settings; distinctive and prominently displayed form that details
specific wishes on medical interventions; education of all those involved
(patients, families, and health care professionals); revision of the template forms
based on feedback and a system to monitor distribution of forms, education and
quality improvement.
DNR orders
The self-reported prevalence of DNR policies in U.S. nursing homes has risen
substantially.69 However, DNR orders are frequently misunderstood, rarely
discussed, and poorly implemented.16 Patients may overestimate the prognosis
following in-hospital resuscitation, with most surveys reporting that less than
15% of people survive to discharge. A systematic review (search date 2005)
found that many residents misinterpreted the terms “DNR” and “futility”.58 The
SUPPORT study included patients with life expectancy less than 6 months and
reported that only 47% of physicians knew their patients’ CPR preferences,
46% of DNR orders were written within the last 2 days before death, and 38%
of these patients had spent more than 10 days in an ICU, on a ventilator, or in
coma before dying.
Mechanical ventilation
Ideally, mechanical ventilation should be performed only if consistent with
patients’ treatment goals. The SUPPORT study found that ventilator withdrawal
patterns vary substantially, with communication being the main predictor of
whether ventilation was withdrawn.23 Another study demonstrated that 15% of
clinicians almost never withdraw ventilation.
Enteral and parenteral nutrition
One recent review found that nutritional support was overused and that
education, guideline implementation, and shared decision making could reduce
its use.70 Another found that gastrostomy tube feeding varies is as high as 90%
in some states among patients with advanced dementia, despite a lack of
evidence that it improves outcomes.23 Many patients would not want life-
prolonging tube feeding, but this decision is often made after incapacity.
Furthermore, one study reported that 15% of patients had feeding tubes placed
despite a recorded preference against them. One pre-post study found that
physician education plus palliative care consultation halved feeding tube place-
ment rates.
Coordination and delivery of care
We found moderate-quality evidence that specialized palliative care services
improve family satisfaction but evidence on patient satisfaction, quality of life,
and symptoms control was less clear-cut.
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A recent systematic review of specialized palliative care (search date 2008)
found 22 RCTs.71 Problems with study implementation or analysis were
common. Insufficient power, including high withdrawal rates, typically limited the
potential for finding a positive effect. Lack of allowance for cluster design,
potential for contamination between groups, and inadequate specification of
primary outcomes or use of appropriate outcome measure was common.
Heterogeneity precluded meta-analysis. The best evidence of effectiveness was
for family satisfaction, with 7 out of 10 studies finding a positive effect. It found
some evidence of improved satisfaction with care, with 4 out of 10 studies
finding a significant benefit. Four out of 13 trials found significant improvements
in quality of life. The review identified no good evidence that specialist care
improved symptoms.
Despite the poor quality of trials, use of specialist care teams is increasingly
common and knowing when and how to refer to specialist palliative care
services is important. Indications that usual care is not sufficient include patient
and/or family distress, symptoms not responding to usual management or
needs becoming sufficiently complex to require specialist input.
Social workers
A systematic review on the role of social workers in palliative care underlined
their important role within multidisciplinary teams and emphasized how they
have traditionally contributed to psychosocial and spiritual concerns, completing
advance directives, counseling, and advocacy.72 The review identified inad-
equate education and role conflicts as major barriers to more effective social
worker involvement.
Nursing homes
The role of hospice services within nursing homes has also been studied. One
RCT (205 nursing home residents) found that use of a structured interview
designed to identify nursing home patients appropriate for hospice care
increased hospice referrals, improved family ratings of the care and decreased
utilization of acute care resources compared with usual care.73
Volunteers
A systematic review found that the work of palliative care volunteers benefited
dying patients and their families, health care professionals, and the volunteers
themselves.74
Discrepancies in service delivery in patients with advanced
chronic disease
A recent review from the U.K.53 identified 1 large retrospective study of
differences in care between people with COPD and lung cancer (1,490 had
COPD, 349 had lung cancer, and 110 had both lung cancer and COPD, all of
whom died in the previous 6 months).75 It demonstrated that patients with
COPD had twice the odds of being admitted to the ICU and higher medical
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costs, but received fewer opiates and benzodiazepine. The review concluded
that palliative care was not available for people with advanced COPD, despite
having poor prognosis with greater disability, lower quality of life, and worse
depression than lung cancer patients and greater use of ICUs.
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PART 2. EVIDENCE REVIEW: SYMPTOM
ASSESSMENT AND MANAGEMENT
Symptom assessment
Bringing relief of suffering to people with advanced illness is largely dependent
upon the early identification and assessment of pain and other problems,
physical, psychosocial and spiritual, as implied by the WHO definition of
palliative care.7 In addition to improving patient/family care, regular assessment
helps to identify those in need of referral to specialist palliative care services.
The high incidence of cognitive impairment, fatigue and comorbidities make
ease of comprehension and speed of completion desirable qualities in an
assessment tool in this population.76 Many seriously ill patients are simply too
unwell to complete detailed instruments.
Multidimensional tools assess a variety of symptoms, rather than assessing an
individual symptom—e.g., pain—in isolation. One example of a practical and
simple multidimensional assessment tool that can be incorporated into busy
daily practice is the Edmonton Symptom Assessment System (ESAS): 10 visual
analog scales covering physical and psychological symptoms, and global sense
of well-being).77 A multisymptom tool, the Memorial Symptom Assessment
Scale (MSAS): 32 physical and psychological symptoms, is a more thorough
but much longer instrument that has been validated in cancer and noncancer
patients.78 Although regular use of these tools helps to build up a clinical profile
of symptom severity over time, they do not provide complete symptom evalua-
tion in themselves and need to be incorporated into a holistic clinical assess-
ment of the patient. Assessment tools focused on specific symptoms are
mentioned in the introductory sections of the symptom chapters below.
For physicians or health care institutions interested in an overview of the best
available symptom assessment and outcome measurement tools, the Toolkit
project has developed an evidence-based online resource, which provides
access to an authoritative bibliography of over 200 reviewed instruments for 11
palliative care domains.79 Building on this work, a recent systematic review
(search date 2005) identified 64 further measures of outcomes in end-of-life
care and evaluated their use in intervention studies.80 Compared with the
Toolkit, this review places a greater emphasis on specific measures of palliative
care or end-of-life care, especially those with psychometric aspects. Another
valuable resource is the City of Hope Pain and Palliative Care Resource Center
web site at http://www.cityofhope.org/prc/.81 Although most of the evidence
base for outcome measures in palliative and end-of-life care comes primarily
from the area of cancer, there is still a need for reliable and valid measures in
certain areas within cancer (e.g., depression in cancer), but most urgently in
other chronic conditions.82 In addition, most current measures have been tested
in just a single setting, whereas most seriously ill patients are managed at
multiple sites of care.80 Measures, therefore, should be more longitudinally
oriented and be applicable across settings. Few measures have been evaluated
for use in an outpatient setting, although this is the most frequent location for
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care.82 Culture has been found to have an impact on patient and caregiver
experience of serious illness, but ethnicity-specific measures are also lacking.80
Symptom prevalence at the end of life
Recent systematic reviews have evaluated the prevalence of symptom distress
in patients with incurable cancer83 as well as far advanced chronic disease.84
The first review (44 studies, 25,074 patients with incurable cancer) identified 37
symptoms assessed in at least 5 studies. Five symptoms occurred in >50% of
patients (pooled prevalence): fatigue (74%), pain (71%), lack of energy (69%),
weakness (60%) and appetite loss (53%).83 During the last 2 weeks of life,
weight loss (86%) was found significantly more often than earlier in the course
of illness, whereas pain (45%), nausea (17%) and urinary symptoms (6%) were
less frequent during the last 1 to 2 weeks of life. In these final 2 weeks, fatigue
(88%), weight loss (86%), weakness (74%) and appetite loss (56%) were noted
in >50% of patients. The second review (64 studies) compared the prevalence
of 11 common symptoms among end-stage patients with cancer, AIDS, heart
disease, COPD and renal disease.84 Although the prevalence of these symp-
toms varied widely between studies, the overall distribution among the 5
diseases was homogenous, indicating a common pathway toward death for
cancer and noncancer diseases. Pain (34% to 96%) and fatigue (32% to 90%)
were present in greater than 50% of all patients. Breathlessness was also
common overall, but was most consistently present among patients with COPD
(90% to 95%) and heart disease (60% to 88%).
Pain
Pain—one of the most feared and debilitating symptoms among patients—is
common in people with cancer and other advanced chronic conditions. Pain
prevalence was 35% to 96% in 19 cancer trials involving 10,379 participants
(search date 2004); 63% to 80% in patients with AIDS (3 trials, 942 people),
41% to 77% in patients with heart disease (4 trials, 882 people), 34% to 77% in
patients with COPD (3 trials, 372 people), and 47% to 50% in patients with
renal disease (2 trials, 370 people).84
Pain assessment
Pain assessement needs to be performed daily and, in its simplest form, using
a numeric rating scale (0 to 10 or 0 to 3) as it is directly linked to adequate pain
management. The literature provides a wide range of more elaborate pain
assessment tools of varying detail and content.85 An expert panel prioritized the
following pain dimensions identified by a systematic review of instruments in the
palliative care of advanced cancer (search date 2003):
1. Pain intensity
2. Temporal pattern
3. Treatment and exacerbating relieving factors
4. Pain location
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5. Pain interference.
The temporal facet of pain was rated as particularly important in palliative care
because of the high prevalence of breakthrough pain. The review concluded
that the optimal assessment tool for the palliative care setting should be precise
(high validity and reliability), brief, and have the flexibility for use in different
populations and situations. A robust/vigorous computerized tool was preferable
to a paper questionnaire.
The Toolkit recommends the McGill Pain Questionnaire (MPQ) and its short
form (SF-MPQ: 11 questions on sensory quality of pain; 4 questions on affective
dimension of pain; 4-point scales) as well-used, valid, and manageable pain
scales, and both the Edmonton Symptom Assessment System (ESAS), and
Memorial Symptom Assessment Scale (MSAS) for assessing pain as part of a
multidimensional instrument.86
Pain assessment can be particularly difficult in people with dementia.87 How-
ever, a prospective study of 160 dementia patients in a hospital setting found
that more than 90% of people with mild or moderate dementia and 40% of the
15 patients with severe dementia were able to complete at least 1 of 4
evaluated self-assessment scales. Pain was mainly musculoskeletal and rates
were similar in all three dementia severity groups. There was only a moderate
correlation between self-assessment scales and an observational pain scale,
which underestimated patients’ estimate of pain. The City of Hope Pain and
Palliative Care Resource Center web site provides access to a wide range of
instruments and a comparison of 10 pain assessment tools in nonverbal older
adults.88
Cancer pain management
Organic causes of cancer pain may be directly linked to the tumor itself (e.g.,
through infiltration and/or compression of nervous roots or visceral tissue, bone
involvement), indirectly related (e.g., muscular contracture, lymphedema, para-
neoplastic syndrome) or due to treatments (e.g., mucositis secondary to
radiochemotherapeutic interventions, postoperative pain).89 The pathophysiol-
ogy of cancer pain is also very complex, including nociceptive, somatic, visceral
and neuropathic components. The therapeutic approach may need to reflect the
multidimensional character of this type of chronic pain through the use of
different drug classes, often in combination, to increase efficacy and minimize
toxicity.
Best practice in the use of analgesics is led by the following principles:90
+ giving the right analgesic at the right dose and the right time
+ administering by the most appropriate route (preferably oral)
+ increasing to the maximum dose before moving to a new agent
+ always considering coanalgesics
+ managing adverse effects
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+ one clinician taking the lead role in the prescribing of opioids.
The extensively validated WHO analgesic ladder offers a stepwise approach to
the use of analgesic drugs. It suggests starting with a nonopioid (acetami-
nophen, NSAIDs or aspirin) and if pain is insufficiently controlled, progressing
to a combination opioid (e.g., codeine or oxycodone plus acetaminophen) and,
if required, to a strong opioid (e.g., morphine, hydromorphone, buprenorphine,
hydrocodone, tramadol, fentanyl, methadone). Acetaminophen is contraindi-
cated in patients with liver disease and 4 g/day is the dose limit. NSAIDs
increase the risk of renal failure and GI bleeding, and are particularly risky in
the elderly for whom opioid analgesics are usually a safer option. Analgesics
may be combined with adjuvant drugs such as corticosteroids, anticonvulsants,
tricyclic antidepressants, or bisphosphonates for specific pain syndromes.89 If
used correctly, the WHO ladder has been shown to lead to adequate control of
cancer-related pain in 70% to 100% of patients.90 However, this needs to be
regarded as one part of a comprehensive strategy for managing cancer pain,
integrating analgesic pharmacotherapy with disease modifying treatment and
nondrug measures. Consultation with a palliative care specialist or anesthesi-
ologist is indicated for the subset of patients in whom the WHO ladder does not
lead to effective pain relief.91
NSAIDs have also been successfully used in combination with opioids for the
treatment of moderate to severe pain and have demonstrated a relevant opioid
sparing effect.90 Another approach used in advanced cancer is to “jump start’
analgesia using strong opioids, as in 1 RCT (100 patients with mild to moderate
pain), which demonstrated their superior analgesic efficacy and reduced need
for treatment changes compared with treatment according to the WHO ladder.92
A recent systematic review (search date 2007) found high-quality evidence for
treating cancer pain with opioids and NSAIDs, metastatic bone pain also with
radiotherapy and radionuclides.8 Less-consistent evidence supports the use of
multidisciplinary teams in managing cancer pain and the use of bisphospho-
nates for bone pain or painful complications (e.g., fracture) from bone
metastases.
Opioids in cancer pain
Opioids are the cornerstone of adequate analgesia in moderate to severe
cancer pain. Their activity is due to the interaction with a variety of receptors in
CNS areas along the sensory pathways of pain.89 Unfortunately, mistaken
beliefs and concerns about the risk of addiction, respiratory depression and
excessive sedation still cause patients and health care professionals to avoid
using opioids or to use them in suboptimal doses.90 Clinical experience has
shown that psychological addiction (continued compulsive use despite harm to
self or others) is highly unlikely if opioids are used to manage pain responsive
to opioids, and in doses titrated to the degree of pain. Long-term opioids will
need to be tapered before discontinuation, but the withdrawal symptoms of
physical dependence should not be confused with psychological dependence
(addiction). Respiratory depression is unlikely at recommended doses.
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Morphine is most commonly used for managing moderate to severe cancer pain
due to its proven analgesic efficacy and cost effectiveness.90 Despite lack of
large, robust clinical trials, morphine remains, to date, also the most tested
opioid for this indication. A systematic review (search date 2006) identified 54
RCTs (3,749 people) evaluating the use of oral morphine for cancer pain.93 It
found that morphine was an effective analgesic, with no significant difference in
efficacy between oral immediate (used for dose titration) and modified release
morphine (used for maintenance treatment). An increasing number of other
effective opioids are now available but the evidence is lacking to demonstrate
the clear superiority of fentanyl, hydromorphone, methadone, oxycodone,
hydrocodone or tramadol over oral morphine in terms of analgesic benefit and
tolerability.94
Table 1 outlines the principles of opioid use for the management of cancer pain.
Table 1. Opioid treatment in cancer pain
Starting
dose
+ Usually 10 mg oral immediate-release morphine every 4
hours
+ Previous analgesic requirements also taken into account
+ Lower doses may be sufficient in the elderly and those
with renal impairment
Dosing
intervals
+ Short acting products are usually taken every 4 hours; a
systematic review (search date not reported) found that
dosing frequency predicted onset to analgesia independently
of baseline dose (2 RCTs, 6 single-arm and 1 retrospective
trial with a total of 877 patients);95 time to adequate
analgesia after initiating oral morphine ranged from 6 hours
to 2.3 days
+ Longer dosing interval may be needed for people with
renal impairment
+ Next dose is given based on half-life, before the effect of
the previous one has worn off
+ Although not formally investigated, a double dose at
bedtime is a widely adopted practice of preventing sleep
disruption through pain
Insuffi-
cient pain
control
+ Pain control is reassessed regularly
+ If pain not sufficiently controlled, dose can be increased
by 50% for moderate or 100% for severe pain; in 54 RCTs
identified by a systematic review, the daily doses ranged
from 25 mg to 2000 mg with an average of between 100 mg
and 250 mg.93
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+ In case of breakthrough pain (transient pain characterized
by rapid onset, severe intensity, and is in most cases
self-limiting after an average duration of 30 minutes) during 4
hourly standard-release morphine, 10% to 15% of the
24-hour morphine total dose are usually given as “rescue
medication” and repeated every hour if necessary
+ A recent systematic review (search date 2005, 4 RCTs,
393 participants) found moderate evidence that oral
transmucosal fentanyl citrate (OTFC) was more effective than
placebo or normal-release morphine in reducing
breakthrough pain intensity.96 A subsequent RCT (87
patients) found buccal fentanyl also to be effective in the
management of breakthrough pain in cancer patients.97 Due
to reports of death and adverse events, buccal preparations
should not be substituted with the same dose of OTFC and
fentanyl only be used in people tolerant to opioids.98 More
trials are urgently needed on the use of other opioids to
improve the evidence base for current practice
High
doses
+ Morphine and its derivatives have no ceiling dose; the
right dose is the one that controls the pain without untoward
or unmanageable side effects.
Stable
dose
+ Once adequate pain control with a stable dose has been
maintained for 48 hours using immediate-release morphine,
the medication can be converted to a sustained-release
morphine preparation (given every 12 or 24 hours)
+ Changes to a long-acting oral opioid dose should not be
be made more frequently than every 24 hours; 72 hours for
methadone and transdermal fentanyl
+ Rescue immediate release morphine equivalent to 10% to
15% of the morphine daily dose is also prescribed for
breakthrough pain
Alter-
native
routes of
adminis-
tration
+ An excellent alternative to oral opioids, when a parenteral
route is required, is intermittent or continuous subcutaneous
morphine; both subcutaneous and IV morphine are around 3
times more potent than oral morphine, so for conversion the
24-hour dose or oral morphine is divided by 3 (for example
120 mg total daily oral morphine is equivalent to 40 mg
subcutaneous morphine in 24 hours)
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+ A systematic review (search date 2002) provided limited
evidence from 6 small randomized controlled or crossover
studies (150 people) that continuous subcutaneous infusion
of opioids (CSIO) is effective and safe, and should be
considered when the oral route is problematic or has failed,
the patient has limited intravenous access, adequate
supervision of the CSIO is present, and CSIO will not unduly
limit the functional activity of the patient.99
+ Intramuscular opioid injections are not recommended
(painful, unreliable absorption)
+ Rectal administration of morphine has similar
bioavailability and duration of effect to oral morphine and
does not require dose conversion
+ Transdermal fentanyl is a noninvasive alternative for
opioid-tolerant patients who require stable opioid doses; it
should not be used in an opioids-naïve patient
+ In intractable pain, opioids can also be given centrally,
administered via intracerebroventricular (ICV), epidural (EPI)
or subarachnoid (SA) routes (± a local anesthetic or
clonidine). A systematic review (search date 2003) found no
RCTs on the use of centrally given opioids.100 However, 72
uncontrolled studies in 2,402 patients demonstrated excellent
pain relief in 73% of ICV, 72% of EPI, and 62% of SA
patients, with unsatisfactory pain relief reported to be low in
all treatment groups. Adverse effects such as persistent
nausea, persistent and transient urinary retention, transient
pruritus, and constipation occurred more frequently with EPI
and SA, whereas respiratory depression, sedation and
confusion were most common with ICV.
Adverse
effects
+ Important to counsel patients and caregivers about opioid
toxicities
+ Nausea and vomiting: Occurs in up to two-thirds of
patients starting morphine and lasting up to 7 days; unlikely
once dose is stable; effective treatment with antiemetics (see
Nausea and vomiting below)
+ Constipation: Very common (in up to 90% of patients) and
persistent effect; therapy with softening and stimulating
laxatives (see Constipation below); increased risk of bowel
obstruction with bulk laxatives when there is insufficient oral
liquid intake
+ Drowsiness: Common at start of treatment; usually wears
off after a few days
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+ Cognitive impairment: Minimal in most patients on stable
dose; tolerance develops over a few days; driving not
significantly impaired in alert patients on stable dose
+ Delirium: see Delirium below
+ Dry mouth: Preventative measures include good mouth
hygiene, regular sips of water and sugar-free chewing gum
+ Urinary retention and pruritus: Uncommon; may occur with
spinal opioids
+ Respiratory depression: dose, drug and route dependent;
most often seen with rapid IV infusion or rapid dose
escalation of methadone; other risk factors include renal
failure, limited pulmonary reserve, and concomitant use of
sedating drugs such as benzodiazepines
Poor
analgesic
response
+ Occurs in 10% to 30% of patients
+ Currently, no indicators known to predict in whom this will
occur
+ Possible to rotate to other opioids (e.g., oxycodone,
hydrocodone, methadone, or fentanyl)
+ Success of rotation is variable and unpredictable; in a
prospective study 20% of patients needed 2 or more
switches prior to adequate analgesia
+ Opioid rotation is always an indication for consultation with
palliative care specialist or anesthesiologist91
Opioid
rotation
+ Hydromorphone (extended or immediate release):101 5 to
10 times more potent than oral morphine
+ Oxycodone:102 1.5 to 2 times more potent than oral
morphine90
+ Fentanyl (a lipid-soluble synthetic opioid): 50 to 100 times
more potent than oral morphine; transdermal delivery for up
to 72 hours; similarly effective in equivalent dosing but lower
risk of constipation and daytime drowsiness compared with
oral morphine;94 however, stable serum levels achieved only
after 12 to 24 hours and due to inflexible dosing with patch,
not recommended in opioid-naïve patients or those whose
dose requirement has not stabilized
+ Methadone:103 complex pharmacokinetics and long
half-life; regular monitoring; administered in consultation with
experienced physicians only
Other drug treatments
1. NSAIDs and acetaminophen
A systematic review (search date 2003) found high-quality evidence from 7 out
of 8 RCTs that NSAIDs reduced cancer pain compared with placebo, without
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increasing the rates of side effects.104 Nine out of 13 RCTs found no significant
difference in efficacy between different NSAIDs, but studies in people with
musculoskeletal pain have demonstrated important differences in adverse
effects.105 Reduction in ulcers with cyclooxygenase-2 (COX-2) inhibitors needs
to be weighed against an increase in cardiovascular risk compared with the
older NSAIDs. Ten RCTs compared NSAIDs versus opioids and found no
clinically significant difference between treatments but demonstrated that
NSAIDs were associated with significantly fewer adverse effects (OR = 0.38).104
Four of 8 RCTs found low to moderate evidence that adding a (weak) opioid to
an NSAID increases efficacy but also rates of side effects. Five of 6 RCTs
identified by the review and one additional small RCT106 showed that adding an
NSAID to an opioid may reduce opioid use and escalation. A second additional
RCT found that adding acetaminophen to morphine did not increase analgesia.
107 The review and an additional RCT108 demonstrated no significant difference
between different NSAID/opioid combinations. Renal insufficiency and risk of
bleeding can be significantly worsened by NSAIDs. This is of particular concern
in the geriatric population, many of whom have underdiagnosed or underappre-
ciated renal insufficiency and are at higher than average risk of abnormal
bleeding in association with NSAIDs.109
2. Corticosteroids
There is very low-quality evidence from 1 RCT including 76 people with limited
survival that adding dexamethasone to conventional opioid therapy may not
increase analgesia but reduce the incidence of GI adverse effects.110
3. Ketamine
A systematic review (search date 2007) identified 2 RCTs including 30 people
and concluded that there was insufficient evidence to draw conclusions on the
benefits and harms of ketamine as an adjuvant to morphine in the treatment of
cancer pain.111
4. Neurolytic celiac plexus block
This intervention has only been evaluated in people with unresectable pancre-
atic cancer. In this population, 5 RCTs including 302 patients found that
neurolytic celiac plexus block (NCPB) reduced pain compared with standard
treatment with NSAIDs/opioids at 4 and 8 weeks (search date 2005).112 NCPB
significantly decreased opioid consumption by mean 40 to 80 mg/day and rates
of constipation compared with standard treatment but increased the risk of
intractable diarrhea. There is very limited evidence that bilateral splanchic nerve
blockade may reduce pain and opioid usage more than NCPB.113
5. Neuropathic pain in cancer
Neuropathic pain is caused by nerve damage due to a wide range of etiologies
and is regarded to be less responsive to opioids than other types of pain.
+ Antidepressants
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A systematic review (search date 2005, 61 RCTs, 3293 people) demonstrated
that neuropathic pain could be treated with antidepressants, independently of
any effect on depression.114 One in three patients benefited from tricyclic
antidepressants (amitriptyline, desipramine, imipramine) and the newer drug
venlafaxine. The review found only limited evidence from four small RCTs for
the effectiveness of SSRIs (fluoxetine, paroxetine, citalopram) and insufficient
data to assess effectiveness for other antidepressants such as St Johns Wort
and L-tryptophan. Only three small RCTs assessed antidepressants for the
treatment of postoperative neuropathic pain after breast cancer surgery and
radiotherapy, and found that amitriptyline significantly relieved pain, and venla-
faxine reduced chronic pain and analgesic use in this population. Cardiovascu-
lar adverse effects (e.g., postural hypotension, heart block and arrhythmias)
limit the use of tricyclic antidepressants, especially in older patients. Most
common side effects include sedation and anticholinergic effects such as dry
mouth, constipation and urinary retention). SSRIs have a better toxicity profile
and are free of cardiovascular adverse effects.
+ Anticonvulsants
A systematic review found that one in four patients with neuropathic pain
benefited from gabapentin or pregabalin but reported a lower efficacy with
topiramate.115 Another systematic review of anticonvulsants in neuropathic pain
found little or no clinical benefit from lamotrigine, except in HIV patients
receiving neurotoxic antiretrovirals.116 Rash was sufficiently serious and fre-
quent (7% incidence), so that its use cannot be recommended unless all other
options have failed. One RCT (63 cancer patients) provided very low-quality
evidence that adding gabapentin to opioids may reduce neuropathic pain more
than opioid treatment alone.117
+ Opioids
A systematic review (search date 2005, 23 RCTs in 727 patients with neuro-
pathic pain) found mixed results from short-term trials (14 RCTs, <24 hours)
using morphine, alfentanil, fentanyl, meperidine or codeine found in the man-
agement of neuropathic pain.118 However, intermediate-term trials (9 RCTs,
median = 28 days; range = 8 to 70 days) using morphine, oxycodone,
methadone, or levorphanol demonstrated opioid efficacy for spontaneous
neuropathic pain. Opioids reduced pain intensity scores compared with placebo
in seven RCTs. Three RCTs showed tramadol to be effective in patients with
painful polyneuropathy or postherpetic neuropathy.115 A systematic review
evaluating the use of buprenorphine in neuropathic pain (search date 2006)
identified 2 RCTs comparing transdermal buprenorphine versus placebo in
people with chronic pain, including 52/294 participants with neuropathic pain.119
Both suggested that buprenorphine may improve quality of sleep and reduce
the need for rescue medication in this population.
+ Systemic administration of local anesthetics
A systematic review (search date 2004) identified 30 RCTs in people with
neuropathic pain due to injury and cancer, and found that lidocaine and
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mexiletine significantly reduced neuropathic pain compared with placebo, and
were equally effective as carbamazepine, amantadine, gabapentine or mor-
phine in terms of efficacy or adverse effects.120
+ Spinal cord stimulation
Spinal cord stimulation (SCS) is commonly used in patients with neuropathic
pain accompanying partial lesions of nerves, nerve roots and the spinal cord in
chronic pain but evidence in palliative care patients is lacking (search date
2003).121
Nondrug treatments
1. Cognitive behavioral therapy
Psychoeducational care has been shown to benefit adults with cancer in
relation to pain but found it problematic to determine the most effective of the
various types of psychoeducational care.122 Two additional RCTs in 368 cancer
patients with or without chemotherapy showed that CBT (five weekly 50-minute
sessions or 10-contact, 20-week, nurse-administered cognitive-behavioral inter-
vention focusing on symptom management) reduced pain severity compared
with usual therapy.123,124 Whereas tailored CBT was better in the short term (at
1 month), standard CBT (proved to be more effective at 6 months. In breast
cancer patients, 7 studies including 484 women found that CBT techniques
reduced pain in 69% of participants compared with control groups (search date
2004).125 Interventions included relaxation (± visualization, cognitive restructur-
ing, coping skills training, problem solving, or imagery) and hypnosis. Individual
CBT did not produce larger effect sizes, and amount of patient contact was not
significantly correlated with effect size.
2. Reminders
A large RCT (over 300 nurses managing 637 people with cancer in a home
care setting) found that nurse-targetted, patient-specific, 1-time email reminders
highlighting 6 pain-specific clinical recommendations significantly improved
patients’ pain intensity scores compared with controls.126
3. Complementary and alternative medicine
Use of complementary and alternative medicine (CAM) is common among
cancer patients. Among advanced cancer patients enrolling into phase I trials,
90/102 (88%) used at least one CAM modality; 93% and 53% used pharmaco-
logic and nonpharmacologic CAM, respectively; and 47% used both modalities.
127 Vitamin (especially vitamin E and C) and mineral preparations constituted
89% of all pharmacologic CAM used. Seventy-one percent of respondents took
nonvitamin/mineral agents, with green tea (30%), echinacea (13%), and essiac
(10%) being the most popular. Prayer and spiritual practices were the most
commonly used nonpharmacologic CAM (52%) and chiropractors the most
frequently visited nontraditional medicine practitioners (10%). CAM modalities
were used more frequently by women (54% vs. 40% in men). In another survey
(212 advanced cancer patients enrolling into phase I trials) increased CAM use
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was associated with younger age, worse stated prognosis, and poorer quality of
life.128 CAM use had no affect on survival.
The majority of patients are reluctant to disclose their use of CAM to their
physician, so it is advisable for health care providers to initiate a discussion
about CAM in order to maintain an open and honest patient–doctor relationship,
encourage adherence to conventional treatment, and monitor adverse effects
and interactions with cancer drugs. The evidence base is growing but consists
mostly of low-quality, small, and poorly reported studies.
Systematic reviews and additional RCTs found promising results for massage
with or without aromatherapy, reflexology, hypnosis, imagery, support groups,
acupuncture, healing touch, and EMG biofeedback-assisted relaxation sessions
but study quality overall was too low to draw definite conclusions. 129,130,131,132
Another systematic review (search date 2006) identified 41 RCTs of low quality,
which found no significant difference between Chinese herbal medicines and
analgesic drug treatment.133
Metastatic bone pain
Metastatic bone cancer is a frequent and serious complication of advanced
disease that occurs in approximately 70% of people with prostate and breast
cancer, and 30% of cases of thyroid, lung and bladder cancer.134 Metastatic
bone lesions are radiographically classified as either osteolytic (e.g., in breast
cancer), or osteoblastic (e.g., in prostate cancer).
The mechanism of metastatic bone pain is uncertain, but generally has three
distinct clinical patterns:
+ Background pain: deep and aching in quality; increasing in intensity with
disease progression
+ Spontaneous, often intense pain
+ Pain associated with physical movement.
The principal complications of bone metastases are severe pain, spinal cord
compression, and pathologic fractures.
Patients with metastatic bone pain need to be managed using an individualized
and multidisciplinary approach with local external beam radiotherapy, support-
ive care with analgesics (opioids and/or NSAIDs/acetaminophen) and biphos-
phonates, systemic treatment (hormone or chemotherapy), and in selected
patients radionuclides. The ideal therapy remains a subject of considerable
debate among palliative care physicians.
Analgesics
According to the WHO ladder, analgesics are the first-line treatment of
metastatic bone pain, although the RCT base for this approach is limited.135 In
people receiving radiotherapy, an RCT (460 people with bone metastases)
found that transdermal fentanyl offered more effective pain relief and a lower
overall rate of side effects than codeine plus acetaminophen.136
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External beam radiotherapy
A systematic review found high-quality evidence for the effectiveness of
palliative radiotherapy from 16 RCTs involving 5,000 cancer patients and
comparing multiple fraction 30Gy radiotherapy versus single fraction
radiotherapy.137 A meta-analysis of the results indicated no significant differ-
ence in complete pain relief or overall bone pain relief between the 2 treatment
groups.
Radiopharmaceuticals
Radioisotopes or radiopharmaceuticals (Strontium 89 [148 MBq IV], Samarium
153 [37 MBq/kg IV], Rhenium 186 [1295 MBq IV]) are administered by IV
injection or locally in areas of active bone turnover, and emit beta particles that
result in cytotoxic irradiation of adjoining malignant cells.134 High-quality evi-
dence from RCTs demonstrated that strontium 89 (with or without radiotherapy)
and Samarium 153 reduced metastatic bone pain compared with placebo and
should be considered in people with multiple active bone lesions when pain
control with analgesics is unsatisfactory.138 The most common side effects in
the studies were thrombocytopenia and neutropenia, which were usually slight
and reversible. Further RCTs are required to evaluate newer radiopharmaceu-
ticals and combination treatments with other systemic therapies.
Biphosphonates
Biphosphonates are specific inhibitors of osteoclast-mediated bone resorption.
In addition to alleviating bone pain, they reduce hypercalemia and the risk of
subsequent fractures. Biphosphonates require long-term therapy and, accord-
ing to a systematic review, should be considered where analgesics and/or
radiotherapy are inadequate.139 An additional RCT of women with metastatic
bone cancer found low-quality evidence of less pain but more severe adverse
reactions with ibandronate (2 mg and 6 mg dosages) compared with placebo.
140 Another systematic review specifically in patients with advanced prostate
cancer with bone metastases found that clodronate and sodium etidronate are
more likely to produce a pain response and decrease analgesic use than
placebo.141
Radiofrequency ablation
A systematic review142 identified very low-quality evidence that radiofrequency
ablation (RFA) produced significant pain relief for cancer patients after failed
standard treatments.143
Hormonal therapy and chemotherapy
Hormonal therapy is effective in patients with breast or prostate cancer.135
Tamoxifen and aminoglutethimide relieve metastatic bone pain in about 1 in 2
breast cancer patients, and antiandrogens, estrogens and orchiectomy (surgi-
cal or chemical) can dramatically decrease bone pain within 24 hours in
patients with prostate cancer. Chemotherapy can reduce tumor volume and
pain in a wide range of cancers. The analgesic impact from chemotherapy is
dependent on the timing of response to treatment; for most patients who are
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chemotherapy responders, a positive effect is noted within 2 weeks and may
last for many months. Unfortunately, with both hormonal and chemotherapy
pain recurrence is common as patients tend to become refractory to treatment.
Calcitonin
Calcitonin, a hormone produced by the thyroid gland, lessens the amount of
bone resorption and thus slows the rate of bone destruction.144 A systematic
review identified 2 small RCTs that found no significant decrease in total pain
reduction with calcitonin compared with placebo.145
Noncancer pain in advanced chronic illness
Opioids are increasingly used in the management of chronic noncancer pain.
They showed good short-term efficacy in 15 RCTs including 1,145 people with
noncancer neuropathic or musculoskeletal pain conditions, with a mean
decrease in pain intensity in most studies of at least 30% (search date 2003).146
Adverse events were experienced by around 80% of participants, the most
common ones being constipation (41%), nausea (32%) and somnolence (29%).
There was insufficient data to draw conclusions on long-term effects of opioid
treatments such as tolerance and addiction. We found no evidence addressing
pain management in other advanced chronic conditions. However, variable
literature indexing for advanced chronic illness and palliative care may have
limited the comprehensiveness of our searches, so conclusions about interven-
tions not supported by high-quality evidence need to be regarded with caution.
Dyspnea
Dyspnea (breathlessness) is a common and disabling symptom in advanced
cancer, COPD, and heart failure, and tends to increase in patients approaching
death.147 A number of interventions are available, but may be underused. A
study of late-stage cancer patients reported that >60% had been dyspneic for
>3 months, and that most had not received any treatment.148
Assessment of breathlessness
The lack of a universally accepted measurement scale for breathlessness
hinders clinical practice and research aiming to appraise the efficacy of
interventions. Most dyspnea assessment scales identified by systematic
reviews (search dates 2005) had been evaluated only in chronic respiratory
disease, but not in cancer or palliative care.149,150 The unidimensional Visual
Numeric Scale, Numerical Rating Scale (NRS), and modified Borg Scale were
noted as most suitable for measurement of severity in clinical practice, whereas
the Japanese Cancer Dypsnea Scale (CDS) was found to be valuable for
assessment of the quality of breathlessness.
Management of dyspnea
Many of the studies reported in this section were identified and presented in a
systematic review by Lorenz and colleagues (search date 2005; literature
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surveillance up to January 2007), which reported the published evidence for
interventions aimed at palliation at the end of life.8
Oxygen
High-quality evidence from 20/22 RCTs showed that oxygen improved symp-
toms during short-term exercise in COPD, but there was only weak evidence of
any benefit in patients with COPD at rest, heart failure, or cancer (3 small
studies and 1 subsequent RCT151).8 Another systematic review found weak
evidence and mixed results from small studies in patients with advanced
cancer, most of whom were hypoxic at the outset.152 However, a recent review
has suggested that even in hypoxic patients, both oxygen and air can improve
dyspnea in patients with cancer, and that before either of these is tried, the
patient may be offered a fan.153
Opioids
There is high-quality evidence of a benefit from opioid use in COPD (12 RCTs),
but poor-quality evidence of benefit in cancer (2 RCTs), according to a
systematic review with a search date of 1999.154 A meta-analysis of 9 studies
found that oral or parenteral opioids reduced dyspnea compared with placebo,
but 3 studies found no benefit from nebulized opioids. Subsequent RCTs in
patients with COPD and advanced cancer confirmed the benefit from oral
morphine for improved subjective dyspnea and sleep, without compromising
respiratory function.155 The most common side effects of opioids reported in the
reviews were constipation, nausea and vomiting. Clinicians might be wary of
prescribing opioids in palliative care, because of a theoretical effect of respira-
tory depression, but this does not appear to be supported by the literature.
Anxiolytics
Although not supported by RCT evidence, low-dose phenothiazines and benzo-
diazepines are widely used in patients with breathlessness requiring sedation
or anxiolysis.153 They should be given in combination with nonpharmaceutical
anxiety-reduction interventions. Phenothiazines (e.g., 6.25 mg oral levomepro-
mazine) are often preferred to benzodiazepines as the evidence base is even
weaker. The long half-life of oral anxiolytics may lead to accumulation and
prolonged sedation. A small RCT of terminally ill cancer patients reported that
subcutaneous midazolam (5 mg every 4 hours) might be a safe and effective
adjunct to morphine in the treatment of dyspnea.156 The starting dose used in
the RCT was higher than recommended by other sources (5 to 10 mg in 24
hours subcutaneously; titrated according to the patient’s wishes with 2.5 to 5 mg
as needed). Midazolam has a half-life of 5 hours and no active metabolites.
High-quality trials are urgently required evaluating the effectiveness of anxiolyt-
ics on dyspnea in palliative care.
Nondrug and complementary therapies
Apart from high-quality evidence from a meta-analysis of 20 RCTs showing a
benefit from pulmonary rehabilitation in advanced COPD,157 there appears to
be a paucity of evidence across other interventions (e.g., supervised exercise or
32 © BMJ Publishing Group 2008
muscle training, care delivery interventions, nursing interventions and pro-
grams, nutrition, psychotherapy, reflexology) and other palliative care
conditions. A systematic review demonstrated weak evidence from 11 RCTs
and 2 controlled clinical trials, and was unable to produce any recommenda-
tions in respect of a range of alternative therapies.158 Two RCTs evaluating
acupuncture, one in advanced cancer, the other in advanced respiratory
disease (cystic fibrosis, COPD and pulmonary fibrosis) found low to moderate
evidence and mixed results.159,160 There is a need to undertake more and better
research into the effectiveness of complementary and alternative therapies in
palliative care situations.
Radiotherapy
Palliative radiotherapy has been evaluated for relieving respiratory symptoms in
patients with lung cancer and mesothelioma only. There is moderate evidence
of symptomatic benefit for dyspnea, cough and hemoptysis for people with
nonsmall-cell lung cancer. Two reviews, covering mainly the same RCTs, did not
identify any regimen that provides optimal palliation, although there was a
tendency for both more harms (in particulare esophagitis) and increased
benefits to result from higher doses.161,162 They concluded that “the majority of
patients should be treated with short courses of palliative radiotherapy, of 1 or 2
fractions”. Our literature search found insufficient evidence in mesothelioma163
and no evidence in other lung malignancies. No patients with mesothelioma
who were treated at a dose of 20 Gy had adverse effects attributed to radiation,
whereas in contrast, most of those receiving total doses of 38.5 to 71 Gy
suffered severe and progressive injury to the irradiated lung.
Malignant pleural effusion
Malignant pleural effusion develops in approximately 50% of patients with
metastatic cancer— particularly breast and lung cancer—and causes morbidity
such as cough and dyspnea. Management is usually with pleurodesis, which
prevents reaccumulation of the fluid and thereby reduces symptoms.164
Five RCTs (228 patients) found that the use of sclerosants (mitozantrone, talc
or tetracycline) significantly reduced recurrence of effusion compared with
pleurodesis using saline or tube drainage alone, with 10 RCTs (308 patients)
reporting talc to be the most efficacous type of sclerosant (systematic review
with search date 2002).164 Comparing 2 agents used for chemical pleurodesis,
an additional RCT (110 people) found that talc sclerosants also reduced the risk
of recurrence of effusion compared with quinacrine.165 Talc sclerosants did not
increase mortality compared with other sclerosants but was associated with
respiratory complications, fever, dyspnea and pain.164 Thoracoscopy plus talc
insufflation was shown by 2 RCTs to be as effective as thoracostomy plus talc
slurry at preventing recurrence of effusion at 30 days.166,167 In patients with low
pH pleural effusion, where talc sclerosants are less effective, limited evidence
from one RCT (87 women with breast cancer) found that thoracoscopic
mechanical pleurodesis may be more effective, and reduce hospital stay and
complication rates.168 There was limited evidence from 1 RCT that bleomycin
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pleurodesis may increase response to treatment at 30 days and delay progres-
sion compared with intrapleural interferon alfa-2-b.169
Fatigue
A recent systematic review defined fatigue as a tiredness that is not improved
by typical measures that normally restore vigor, stressing the subjective,
multidimensional and distressing nature of this phenomenon.170 Approximately
40% of cancer patients experience fatigue at the time of diagnosis and it may
intensify during or after chemotherapy treatment.171 Its prevalence rises to
higher than 75% in patients with advanced cancer.170 Fatigue is also common
among people with COPD and heart failure.
Fatigue assessment
Valid methods to assess fatigue are essential for its treatment. Fatigue, as with
other symptoms, is best evaluated by self-assessment measures, not by the
observations of a health professional. A systematic review identified and
evaluated self-report tools that focused on assessment of adults with fatigue.170
It found that despite efforts to produce fatigue instruments, no gold standard
was available.
Fatigue management
There is good evidence for the effect of psychological and psychoeducational
interventions on cancer-related fatigue, although applying the evidence to
people with advanced disease is difficult.171 There is evidence for a small
benefit from methylphenidate, exercise and energy conservation and activity
management. No reduction of fatigue resulted from administering progesta-
tional steroids, such as medroxyprogesterone and megestrol acetate, paroxet-
ine, or multivitamins. There is insufficient data to recommend any specific
complementary therapies for the treatment of cancer-related fatigue.
As a complex and multifaceted symptom, cancer-related fatigue has been
associated with psychological (anxiety and depression) and physical factors
(hemoglobin and cytokine levels, physical activity), sleep disturbances and
symptom burden, but not tumor stage or treatment type.172 In most patients,
fatigue has multiple causes and will require an individualized treatment plan.171
Psychological and psychoeducational interventions
A systematic review (search date 2005) identified 24 RCTs using a broad range
of psychological interventions (11 CBT, 3 educational programs, 3 supportive-
expressive group therapy, and 3 supportive therapy, 4 RCTs were specifically in
people with meta-static disease) and conducted a meta-analysis that showed a
small improvement in cancer-related fatigue with psychological interventions
(standardized mean difference: 0.10, 95% CI 0.02 to 0.18).173 A second
systematic review identified one RCT (235 women with metastatic breast
cancer at the end of life), which found that group psychotherapy was beneficial
for reducing fatigue.171 An RCT of 113 patients undergoing chemotherapy for
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breast and lung cancer showed that a tailored supportive intervention including
teaching, counseling, and support reduced fatigue, pain, and total symptom
burden. Similarly, a subsequent RCT of 103 people receiving chemotherapy
compared an investigator-designed information pack combined with monthly
home visits by support nurses versus usual care; the nurses assessed fatigue,
provided psychological support, and coached participants in self-care.174 The
intervention significantly lowered fatigue and the impact of fatigue on valued
pastimes.
Exercise interventions
A recent systematic review (search date 2007) found moderate-quality evidence
of a small improvement in cancer-related fatigue with an exercise intervention
(1664 people, mostly with breast cancer, SMD −0.23, 95% CI −0.33 to
−0.13).175 Results were not broken down by disease stage.We found insufficent
evidence to assess the effects of Tai Chi or qigong on cancer-related fatigue.
176,177 Recent European guidelines found strong evidence that aerobic exercise
reduced fatigue in cancer survivors and those undergoing cancer treatment.178
However, they found little evidence for people with advanced disease and
impaired performance.
Exercise conservation and energy management
A systematic review (search date not reported) identified 1 multisite RCT that
showed a small but statistically significant effect on fatigue with semistructured
exercise conservation and energy management intervention in people initiating
treatment for cancer (P = 0.01), applying the result to people with advanced
disease is difficult.171
Drug treatments
A systematic review (search date 2007) identified 2 RCTs (264 people) that
showed methylphenidate (a CNS stimulant, 10 to 20 mg/day) having a small but
significant positive effect on fatigue compared with placebo (P = 0.02).179 An
additional small RCT (68 people) found a small but nonsignificant trend toward
reduction in fatigue with methylphenidate.180 The review noted an increased risk
of harm from methylphenidate compared with placebo, although the difference
did not reach statistical significance.179 Adverse reactions can include stroke
and MI, elevated BP, seizures, visual symptoms, headache, insomnia, nausea,
decreased appetite, anxiety and palpitations.181
The systematic review found no significant difference between progestational
steroids such as medroxyprogesterone or megestrol acetate (4 heterogeneous
RCTs, 587 people) or paroxetine (2 RCTs, 645 people) versus placebo for the
treatment of cancer-related fatigue.179
Complementary therapies and nutritional supplements
A systematic review (search date 2006) identified 21 clinical trials, but none of
sufficient quality to recommend any complementary therapy for cancer-related
fatigue.182 Tested interventions included acupuncture, aromatherapy, adenosine
triphosphate infusions, healing touch, hypnosis, mistletoe extract, American and
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Asian ginseng, levocarnitine, massage, mindfulness-based stress reduction,
polarity therapy, relaxation, support group and Tibetan yoga. More research is
needed to clarify whether any of these modalities can be useful in improving
fatigue and how they might apply to people with advanced disease.
Hematopoietic growth factors in people with anemia
Although hematopoietic growth factors reduce fatigue in people with anemia
recent trial evidence has confirmed shortened overall survival and/ or time to
tumor progression and their recommended use is now restricted.183,179
Improving sleep disturbances
In the general population inadequate or unrefreshing sleep is generally associ-
ated with increased risk of medical and psychiatric illness, and reduced quality
of life. It is likely that this holds for people with advanced disease. Sleep
disorders are reported by 30% to 50% of cancer patients during all phases of
cancer care, twice the level of the general population.184 However, a systematic
review (search date 2005) found no randomized evidence on pharamacologic
treatments for sleep disturbances.184 It found only 1 small RCT (42 people with
advanced cancer). This RCT compared a 4-week course in aromatherapy
massage and massage alone and no intervention. It found that both interven-
tions significantly improved sleep scores compared with no intervention. We
found 1 additional small RCT (57 breast cancer survivors with insomnia)
comparing 8 weekly sessions of group CBT versus waiting list controls.185 It
found that CBT significantly improved sleep indices and reduced the frequency
of medicated nights.
Distress, depression and mental health
Psychological distress, including grief, sadness, despair, fear, anxiety, loss and
loneliness occur among most people at some time with advanced disease.186
Distress is underrecognized and undertreated,187 but with support many people
can achieve equanimity and acceptance.186 The clinician has an important role
in assessing stressors and helping the patient to identify coping strategies.
Assessment and management
Symptoms present across a continumum and evaluation of psychological
symptoms is required to identify those at high risk of psychiatric disorders.
Clinicians have a key role in screening for mental illness and initiating first-line
treatment. With serious mental illness a collaborative approach with mental
health specialists for patients with personality disorders, major mental illness,
and substance abuse problems is recommended. About 50% of patients with
advanced cancer meet criteria for a psychiatric disorder, the most common
being adjustment disorders (11% to 35%) and major depression (5% to 26%).56
There is less good evidence in people with cardiac, pulmonary renal, or
neurologic disease. Although anxiety has a high prevalence in this population,
this is often not about death but about symptom management, isolation and
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family needs.188 Symptoms such as fatigue or chronic pain, although common
in this population, can also present due to somatization of an underlying
depression.
A systematic review of psychological distress in cancer patients found that
clinicians needed training in skills for assessing and managing distress.187 It
recommended treating patients holistically and shared decision making with
uninterrupted patient talk time. It also found that if clinicians were willing to use
emotional words, this facilitated patient expression. Self-completed quality-of-
life questionnaires, screening tools for distress, and patient question prompt
cards can help with the diagnosis. Providing time for open, patient-led conver-
sations, active listening and responding to patients’ emotional cues are
important. A tendency to overrely on symptoms such as depressed mood or
crying should be avoided as these are not sensitive indicators, particularly in
this population.
The keys to good management are effective communication and trust, control of
symptoms, and attention to psychological issues. Symptoms need to be actively
solicited because patients may view psychological distress as being appropriate
to their situation, may consider that distress reflects a lack of coping skills, or
simply believe that it is not appropriate to report such issues to their clinician.
Clinicians themselves may adopt distancing techniques to avoid discussions
that can be seen as an emotional challenging and time-consuming, although
effective communication is beneficial for both patients and doctors.
Evidence on the effectiveness of treatments
We found low-quality evidence that behavioral techniques may reduce depres-
sion and improve functioning. We found little good-quality evidence on pharma-
cologic treatments. With complementary and alternative medicines the best
evidence is for aromatherapy and massage (low-quality evidence of a reduction
in anxiety), music therapy (low-quality evidence of improvement in quality of
life), and reflexology (low-quality evidence of an improvement in anxiety and
pain intensity). The Toolkit contains best practice recommendations (see
Appendix A).
Pharmacologic interventions
Anxiety
Despite the high prevalence of anxiety, a systematic review on drug therapy for
anxiety in palliative care (search date 2003) identified no good-quality RCTs on
drug therapy in patients with advanced cancer, end-stage disease, or those
receiving hospice or palliative care.188
Depression
A second systematic review (search date 2005) of treatments for depression in
cancer patients identified 7 trials of pharmacologic agents and four of nonphar-
macologic interventions.189 Only 1 drug RCT was specifically in people with
advanced cancer (163 people with at least occasional evidence of depressed
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mood) and this found limited evidence of a difference between fluoxetine and
placebo on depression. A subsequent RCT (189 people with advanced cancer
but without major depression) found no effect on depression or quality of life
with sertraline compared with placebo.190 Four drug trials in people with cancer
of different stages found no significant difference between different
antidepressants. A small RCT found no significant difference between paroxet-
ine and placebo in people with end-stage COPD.191
Nonpharmacologic interventions
Most studies measured multiple outcomes, including different psychological
outcomes and physical functioning, thus disaggregating which interventions
should be targeted at specific symptoms is difficult.
Cognitive and behavioral therapies
A systematic review (search date 2003) showed moderate-quality evidence of a
small to moderate reduction in distress with behavioral therapy techniques in
women with metastatic breast cancer (standardized mean difference of 0.43).
125 It found very low-quality evidence that individual therapy may be more
effective than group therapy. A previous systematic review (search date 2002) in
patients with advanced cancer (mainly breast cancer) reported from 7 trials that
behavior therapy improved depression, physical functioning, and global quality
of life.192 Four trials of behavior therapy suggested that group support improved
depression and physical functioning. One trial suggested that behavioral
therapy with breathing techniques may improve depression.
Our literature search identified 2 subsequent RCTs. The first RCT (123 people
with advanced cancer) found problem-solving techniques delivered by nurses
reduced symptom severity at 10 and 20 weeks.193 The second small trial
reported that cognitive therapy significantly reduced depression.194
Mindfulness
We found mixed evidence on mindfulness approaches from 2 RCTs in people
with a variety of cancer disagnosis.195,196
Complementary medicine
AROMATHERAPY AND MASSAGE
A systematic review in people with cancer but not exclusively with advanced
disease (search date 2002) identified some evidence of a reduction in anxiety
from massage.129 It found conflicting evidence on additional benefit from
aromatherapy and mixed evidence about depression from 3 trials. A second
systematic review identified 2 RCTs of aromatherapy in palliative care.197 The
larger RCT (103 people) provided very low-quality evidence of an improvement
in overall symptom control. The smaller RCT found no evidence of an effect on
anxiety or depression from massage.
A large subsequent RCT (288 cancer patients with anxiety and/or depression,
43% with advanced disease) found a reduction in anxiety and a smaller
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reduction in depression from aromatherapy message at 6 to 10 weeks.198 Three
small RCTs in pallative care found mixed outcomes with aromatherapy and
massage.199,200,201
MUSIC THERAPY
Music therapists use methods including song writing, improvisation, singing,
instrument playing and music therapy relaxation techniques in palliative care.202
An RCT (80 people with advanced cancer) found improvement in hospice-
related quality of life from music therapy.202 A second review of music therapy
indicated that it may reduce depression and improve well-being in people with
cancer/terminal illness/HIV.203 Similarly, an additional RCT (70 women with
metastatic breast cancer) found short-term improvements in mood, although
differences were not maintained.204
REFLEXOLOGY
One RCT (86 patients with metastatic cancer and their partners) found
low-quality evidence that partner-delivered foot reflexology reduced pain inten-
sity and anxiety postintervention.205
OTHER COMPLEMENTARY THERAPIES
We found insufficient evidence to assess the effectiveness of acupuncture,
therapeutic touch, multisensory stimulation, breathing training, homeopathy,
yoga or guided imagery.197,206,207
Service organisation
Three systematic reviews identified little good evidence on the effects of service
management on mental health outcomes.208,8,189 Breast cancer nurses were
the best-studied service intervention, but all trials were conducted in women
with early stage breast cancer and results would be difficult to apply to women
with advanced disease.
Delirium
Delirium is a common illness/condition in ill elderly people, especially those with
dementia.209 It is also the most frequent complication of hospitalizations among
the elderly. In the SUPPORT study, delirium affected 20% to 30% of people with
cancer, COPD and end-stage liver disease.8 Its prevalence increases to 26% to
44% in terminal cancer, and eventually to 83% in people during their final days.
Delirium is associated with a higher rate of mortality, both during and following
hospitalization.210 A prospective cohort study with patients who had experi-
enced delirium during hospitalization found a 62% increased risk of mortality at
1 year compared with patients without delirium (adjusted survival: 274 days vs.
321 days).211 In people with advanced cancer, delirium was associated with a
significantly lower survival time (21 vs. 39 days). Delirium also increases length
of hospital stay (on average by 7 days), and impaires cognitive and physical
status for 6 and 12 months after hospital discharge, often delaying a return to
the patients’ prior site of residence.209
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The pathophysiology of delirium is not well understood, but abnormal neuro-
transmitter levels, particularly those of acetylcholine and dopamine may be
involved.
Delirium and dementia are closely interconnected; the presence of dementia
increases the risk of delirium. Other risk factors include older age, frailty, severe
illness or multiple comorbidities, polypharmacy, and hospital admission due to
infection or dehydration—all commonly encountered in palliative care. In an
older patient with these risk factors, the addition of one of the following
precipitants may contribute to the onset of delirium:
+ Urinary tract infection/catheter
+ Lower respiratory tract infection
+ Electrolyte abnormality including dehydration,renal failure
+ Constipation
+ Surgery
+ Addition of a new medication often anticholinergic or psychoactive (e.g.,
antihistamines, antispasmodics, tricyclic depressants, benzodiazepines, opioid
analgesics, antiarrhythmics, diuretic, brochodilators, antiparkinsonian agents,
bladder stabilizers)
+ Environmental-intrahospital transfers, absence of reading glasses, use of
physical or pharmacologic restraints
+ Alcohol or drug withdrawal.
Delirium is not detected in 22% to 50% of cases or its symptoms may be
attributed to a primary psychiatric disorder.212 This is not surprising as delirium
may present as hyperactive, hypoactive, or a mixed subtype and with different
combinations of recent-onset variation of consciousness, diminished attention
span, and impaired cognition. Hallucinations and abnormal sleep-wake cycles
may also occur. In addition to symptom variability, factors related to failure to
recognise delirium include pre-existing dementia, older age, and the presence
of sensorial alterations (e.g., failing eyesight).213 Delirium is a clinical diagnosis,
which needs to be made in view of the history of the present illness as provided
by family members, and requires monitoring and comparison with the baseline
situation. The Confusion Assessment Method is a valid, sensitive, specific,
reliable and easy to use instrument for the identification of delirium.214 This tool
can be completed in less than 5 minutes and consists of 9 criteria from the
Diagnostic and Statistical Manual of Mental Disorders, Third Edition, Revised
(DSM-III-R). The diagnosis of delirium requires the presence of 2 criteria (acute
onset and fluctuating course, and inattention) and of either disorganized
thinking or altered level of consciousness. Delirium severity can be assessed
using the Memorial Delirium Assessment Scale (MDAS).215
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Prevention of delirium
The Yale delirium prevention model of care has been found to reduce the
incidence (9.9% vs. 15%) and duration of delirium (105 vs. 161 days) signifi-
cantly compared with usual care (852 people admitted for general medical
care).209,216 This intervention has been translated into routine practice as the
hospital elder life program (HELP),217 which is now used internationally, and
has been shown to reduce the rates and costs of delirium in elderly hospitalized
patients at risk of delirium.214 Effective components of the HELP program
include orienting communication, therapeutic activities, early mobilization and
walking, nonpharmacologic approaches to sleep and anxiety, maintaining
adequate nutrition and hydration, and use of adaptive equipment for vision and
hearing.
General management
Delirium diagnosed on admission to a palliative care unit may be reversible in 1
in 2 patients and an even higher percentage of cases when triggered by drugs,
dehydration or hypercalcemia.213 A systematic review (search date 2006) stated
immediate identification, reduction and potential withdrawal of precipitating
agents (as listed above), and supportive care regarding hypoxia, hydration,
nutrition and mobilization as general management principles of delirium in the
elderly.209 Good care of patients with delirium includes reassurance and a safe
and comfortable environment for the patient as well as provision of information
to the family about the fluctuating nature and clinical symptoms of delirium.
Existing medications
Drugs are the most common cause of delirium.213 After documentation of
previous and existing medications, reduction and possibly withdrawal of andti-
cholinergic and psychoactive drugs should be considered. A proportion of
people who receive opioid therapy develop neuroexcitatory toxicity, either
secondary to a rapidly increasing dose, an accumulation of opioid metabolites
caused by renal impairment, or individual sensitivity to opioids. It is hypoth-
esised that in these patients opioid dose reduction and/or rotation (usually at an
equianalgesic dose with a reduction of 20% to 30%) may alleviate delirium. The
clinical practice of opioid rotation as a means of balancing pain control and
opioid side effects in patients with cancer or chronic noncancer pain is widely
accepted but its evidence is based on case reports and uncontrolled studies.218
A systematic review found that opioid rotation resulted in clinical improvement in
over 50% of patients with chronic pain and poor response to one opioid.219 For
conversion ratios, please see Table 1 on Opioid treatment in cancer pain.220
However, the process of determining the optimal dose is not purely a math-
ematical calculation, but needs to be considered as part of an individualized
and comprehensive evaluation of pain, adverse effect intensity, comorbidities
and concomitant drugs.
Drug treatments
Drug treatments for delirium patients should be reserved for the following
indications:221
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+ Patients who pose a danger to themselves or others
+ Uncontrollable agitation despite nonpharmacologic interventions
+ Anxiety in the presence of agitation or hallucinations
+ Need to control agitation during a diagnostic or clinical intervention.
Antipsychotics
There is consensus based mainly on observational evidence and experience
that haloperidol and other butyrophenones such as dropiderol are effective for
the management of delirium in the palliative care setting. A systematic review
(search date 2006) identified 3 RCTs in hospitalized patients, and demon-
strated that haloperidol treatment was more effective at improving delirium
scores at 7 days compared with placebo.222 The review found no significant
difference in the effect of haloperidol compared with the atypical antipsychotics
risepridone or olanzapine. However, haloperidol improved delirium scores
significantly later than olanzapine, and was associated with significantly higher
rates of dry mouth and dystonia.
Most people with dementia are sensitive to adverse effects from antipsychotics,
especially sedation and extrapyramidal symptoms.223 In people with dementia,
olanzapine and risperidone have been found to increase the risk of sudden
death and nonfatal cerbrovascular events, and should be avoided.224,225,226
Patients on antipsychotic medications should be regularly monitored for QT
prolongation, although this recommendation may not apply in someone already
very near the end of life.221
Other medications
Our literature searches found no clinically important results about the effects of
profolol or barbiturates in people with delirium caused by a terminal illness.
Similarly, we found no high-quality evidence on the effectiveness of phenothi-
azines (chlorpromazine, levomepromazine) compared with placebo, although
these agents are used clinically for treatment of delirium at the end of life,
usually second line to haloperidol. Although benzodiazepines, especially mida-
zolam, are also used extensively for the treatment of delirium in terminally ill
patients, we found no evidence from well-conducted trials that they are
beneficial. A systematic review (search date 2003)227 identified only 1 small
RCT in 30 patients with terminal AIDS reporting that lorazepam actually
worsened delirium and was associated with serious adverse effects, including
oversedation, disinhibition and ataxia.228
Anorexia and cachexia
Loss of appetite (anorexia) occurs in 70% of patients with advanced cancer,
and is often worsened by cytotoxic treatments that lead to dysphagia, nausea
and mucositis.229 Although cachexia (significant weight loss due to disease)
often occurs with anorexia, it is not caused solely by reduced nutritional intake
42 © BMJ Publishing Group 2008
but characterized by a catabolic state with increased resting energy expendi-
ture, preferential loss of skeletal muscle as well as fat, increased proteolysis,
and lipolysis, possibly caused by chronic systemic inflammation and circulating
tumor-derived factors.230,231
Management
Effective treatments to improve appetite in terminally ill people with anorexia
include the progestogen megestrol acetate and corticosteroids.
+ Progestogens: Although systematic reviews have found high-quality evi-
dence that progestins (megestrol acetate [MA] and medroxyprogesterone
acetate) increase appetite and weight gain in cancer patients compared with
placebo, they also increase the risk of adverse effects, particularly lower limb
edema (11 RCTs, 1,767 people: RR 1.74).229,232 A retrospective case-control
analysis of 2,127 elderly nursing home residents with cachexia found no
significant difference in median weight at 6 months between residents with and
without MA, and demonstrated that the median survival of people receiving MA
was significantly reduced compared with untreated residents (23.9 months vs.
31.2 months).233
+ Corticosteroids: Six RCTs (647 patients) found that methylprednisolone,
prednisolone or dexamethasone increased appetite in the short term compared
with placebo, but that the benefit may decrease after several weeks.229 The
review reported no results on survival. Side effects of prolonged use include
osteoporosis, proximal muscle weakness, immunosuppression, delirium and
skeletal muscle atrophy.230
+ Enteral nutrition: Orally consumed supplements (volitional nutritional support
[VNS]) may increase survival in malnourished geriatric patients but neither VNS
nor enteral nutrition via a tube can be recommended in people with cancer or
other advanced chronic diseases.234 No results for weight gain or increase in
appetite were reported.
+ Parenteral nutrition:We identified only 2 RCTs evaluating parenteral nutrition
as part of a combination therapy in cancer patients.235,236 The first RCT (152
people with advanced cancer) found that adding parenteral nutrition to enteral
nutritional support signficantly increased mean BMI at 48 weeks (21.9 vs. 20.5)
and cumulative survival compared with enteral nutrition alone.235 The second
RCT (309 cancer patients with cachexia followed up to 2 years) found that
adding oral and home parenteral nutrition to the cyclooxygenase-1 (COX-1)
selective inhibitor indomethacin plus erythropoietin improved energy balance
but found no significant differences between groups in intention-to-treat
analysis.236 Although not observed in the 2 RCTs, parenteral nutrition carries an
increased risk of line infection and associated sepsis.
+ Other interventions: A systematic review concluded that there was no benefit
from hydrazine sulfate, and that the evidence was inconclusive about the
benefits of metoclopramide, cyproheptadine, pentoxyfylline, melatonin, fatty
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acids and eicosapentaenoic acid, erythropoietin, androgenic steroids, ghrelin,
interferon, NSAIDs, cannabinoids, or thalidomide.229
Dehydration
Reduced fluid intake is common in palliative care patients, caused by a variety
of factors such as physical obstruction, anorexia/cachexia syndrome, general-
ised weakness, bowel obstruction, nausea, decreased level of consciousness
and loss of desire to drink, although in some cases no specific cause may be
identified. High-quality evidence on the management of dehydration is sparse
and routine practice varies widely geographically and between care settings.237
Once treatable differential diagnoses such as delirium or opioid toxicity have
been been assessed, the chosen course of action needs to be decided, if
possible, in discussion with the patient, both as part of advance directive
discussions and when the condition occurs, and with family and staff involved.
There is some observational evidence that terminally ill people may not
experience suffering from terminal dehydration, provided that good mouth
hygiene is maintained.238,239 In a small prospective trial in a comfort care
setting, 20/32 patients (62%) experienced either no thirst or thirst only initially
during their terminal illness. In all cases, symptoms of thirst and dry mouth
could be alleviated, usually with small amounts of fluids, and/or by the
application of ice chips and lubrication to the lips.238 In another small prospec-
tive study of 88 terminally ill cancer patients, perception of thirst was shown to
be associated with hyperosmolality (300 mosmol/kg or more), poor general
condition, stomatitis, oral breathing, and use of opioids.240
Medically assisted hydration, performed either intravenously, subcutanously
(hypodermoclysis) or via gastrostomy, remains a much debated issue among
palliative care physicians. A systematic review (search date 2008) identified
only 5 studies including 2 RCTs (including 93 patients) on the effects of
short-term hydration in terminal cancer, which were deemed insufficient to
make recommendations as trials were either underpowered or of insufficient
quality.241 There was weak evidence that artificial hydration might improve
sedation and myoclonus, but it had no beneficial affect on other outcomes and
increased fluid retention (e.g., pleural effusion, peripheral edema and ascites)
compared with no artificial hydration. We found no evidence on the use of
artificial hydration in the wider palliative care population.
Nausea and vomiting
Nausea, vomiting and retching are all prevalent in palliative care patients.
Emesis is a word used to represent all 3 components of the symptom
complex.76 A recent systematic review in patients with incurable cancer found
that nausea occurred in 17% (6 studies, 2219 patients) and vomiting in 13% of
patients (3 studies, 799 patients) in the last 1 or 2 weeks of life.83 Another
review comparing symptom prevalence in different advanced conditions,
reported that nausea was present in 6% to 68% of patients with cancer (19
studies, 9,140 patients), 43% to 49% of patients with AIDS (2 studies, 689
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patients), 17% to 48% of patients with heart disease (3 studies, 146 patients),
and 30% to 43% of patients with renal disease (3 studies, 362 patients).84
Nausea and vomiting can cause dehydration, electrolyte disturbances and
diminished quality of life for patients and their families, and can negatively affect
a patient’s ability to complete activities of daily living. Chemotherapy-induced
nausea and vomiting (CINV) and other chemotherapy-related toxic effects may
also lead to lengthier hospitalizations and elevated costs, and delay chemo-
therapy for up to 50% of affected patients.242
Assessment of nausea and vomiting
Nausea is a subjective symptom and assessed using a self-report tool (unless
cognitive impairment is an issue), whereas vomiting, as an objective sign/event,
can be assessed by its volume, frequency, and consistency. Retching is not
usually measured independently.
A systematic review (search date 2004) evaluated the validity and suitability of
available tools for assessment of nausea, vomiting and retching in palliative
care patients.76 It found a paucity of agreement regarding assessment tools for
all 3.
For daily clinical assessment, simple visual analogue scales or numerical rating
scales are recommended. Multidimensional tools (e.g., the revised Rhodes
index of nausea, vomiting and retching) are reserved for antiemetic drug trials
and provide specific data on frequency, duration, amount, distress and effect on
functioning.
Treatment approach
There is a large gap in the evidence base regarding high-quality studies in the
management of nausea and vomiting in chronic advance disease other than
related to cancer treatments. In order to optimize treatment and minimize side
effects, the current management of nausea targets specific receptors, which
vary by underlying pathophysiology. The VOMIT acronym is helpful for remem-
bering the causes of nausea, see Table 2.243
Table 2. VOMIT acronym for the major causes of nausea
Cause Receptors
involved
Drug classes Drug examples
V – vestibular Cholinergic
Histaminic
Anticholinergic
Antihistaminic
Scopolamine
patch
Promethazine,
diphenhy-
dramine
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Cause Receptors
involved
Drug classes Drug examples
O – obstructive
(bowel
obstruction
caused by
constipation)
Cholinergic
Histaminic
5HT3
Drugs
stimulating the
myenteric
plexus
Senna products
M – motile
(dysmotility of
upper gut)
Cholinergic
Histaminic
5HT3
Prokinetics
(stimulating
5HT4
receptors)
Prokinetics,
metoclopramide
I –
infectious/
inflammatory
Cholinergic
Histaminic
5HT3
Neurokinin 1
Anticholinergic
Antihistaminic
5HT3
antagonists
Neurokinin 1
antagonists
Anti-
inflammatory
agents
Scopolamine
Promethazine,
diphenhy-
dramine
Ondansetron,
granisetron
Aprepitant
Corticosteroids
Constipation
The prevalence of constipation from opioid utilization for noncancer pain ranges
from 15% to 90%.244,245 Patients following WHO guidelines for cancer pain
management have a constipation prevalence of 23%. In a large U.S. hospice
study, 40% to 63% of patients had constipation.
Management
Bowel prophylaxis (e.g., with senna plus docusate) is recommended in all
people starting opioid treatment.
Oral laxatives
+ Senna, a stimulant laxative, has been shown in an RCT to be similarly
effective as lactulose for reducing the frequency of hard stools in people
prescribed opioids.246 Another RCT indicated that senna may be as equally
effective as the Ayurvedic herbal preparation Misrakasneham in people with
advanced cancer.247
+ Docusate, a stool softening agent, is prescribed in people taking opioids, but
there is no good evidence to support its use.248
+ There is evidence from a systematic review of RCTs that lactulose, an
osmotic laxative, may reduce the number of hard stools compared with placebo
in people taking opioids.246 A systematic review (search date 2003) found that
46 © BMJ Publishing Group 2008
lactulose and and polyethylene glycol 3350/electrolyte solution (PEG) may be
equally effective.249 However, a subsequent RCT comparing lactulose versus
PEG showed that intestinal obstruction or Ogilvie syndrome occurred more
frequently with lactulose than with PEG.250
+ Macrogels (PEG), an osmotic agent, may improve stool consistency com-
pared with placebo in people prescribed opioids.249 There is moderate-quality
evidence suggesting that macrogels may be as effective as lactulose at
reducing the number of hard stools in people prescribed opioids.
+ Our literature search found no clinically important results about the effects of
bisacodyl, sodium picosulfate, isapaghula husk, methylcellulose or magnesium
salts on constipation in people prescribed opioids.
Rectally applied medications
Our search identified one systematic review (search date 2007) and found no
clinically important results about the effects of phosphate enemas on constipa-
tion in people prescribed opioids.251 There were also no clinically important
results about the effects of liquid paraffin, glycerol suppositories, sodium citrate
micro-enemas, and arachis oil enemas on constipation in people prescribed
opioids.
Opioid antagonists
Constipation arises when opioids are used therapeutically because the drug
acts on peripheral opioid receptors in the GI tract, in addition to those in the
nervous system where their analgesic benefits arise. Opioid antagonists can
block GI opioid receptors and so potentially reverse the analgesic effect of
opioids but the main drawback of their use is the difficulty of retaining the
central beneficial effects while preventing constipation.252
A systematic review (search date 2007) identified 2 RCTs, which compared
subcutaneous methylnaltrexone (MNTX) versus placebo in hospice or palliative
care patients with advanced medical illness (mainly cancer, with life expectancy
< 6 months, no bowel movement for over 48 hours or < 3 bowel movements in
the preceding week.253 Both RCTs showed that MNTX significantly increased
the rate of bowel movements within 4 hours without interfering with central
analgesia. Subcutaneous methylnaltrexone bromide has just gained FDA
approval for the treatment of opioid-induced constipation in patients with
advanced illness who are receiving palliative care.254
Another systematic review (search date 2005) identified one RCT of 168 people
with opioid-induced bowel dysfunction, 148 of whom were taking opioids for
chronic pain, primarily back pain.252 The RCT compared dosages of alvimopan
0.5mg and 1.0mg taken once daily versus placebo for 21 days. Significantly
more people taking alvimopan at either dosage had a bowel movement within 8
hours compared with placebo; alvimopan at the 1.0 mg dose significantly
increased the frequency of bowel movements and overall patient satisfaction.
Alvimopan is not approved in the U.S. for opioid-induced constipation.
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Our literature search found no evidence of sufficient quality on the effectiveness
of naloxone, an opioid antagonist which can be taken orally, after conversion
from injectable form.
48 © BMJ Publishing Group 2008
REFERENCES
1. Lorenz K, Lynn J, Morton SC, et al. End-of-life care and outcomes.
Evidence Report/Technology Assessment No. 110. (Prepared by the
Southern California Evidence-based Practice Center, under Contract No.
290-02-0003.) 2004. AHRQ Publication No. 05-E004–2. Rockville, MD:
Agency for Healthcare Research and Quality.
2. Central Intelligence Agency: The World Factbook. Life expectancy in years
by country. 2008 est. Available at: https://www.cia.gov/library/publications/
the-world-factbook/fields/2102.html. Accessed on: May 10, 2008.
3. Boockvar KS, Meier DE. Palliative care for frail older adults: ’there are
things I can’t do anymore that I wish I could …’ JAMA. 2006;296:2245–
2253.
4. Meier DE. Palliative care in hospitals. J Hosp Med. 2006;1:21–28.
5. Bickel-Swenson D. End-of-life training in U.S. medical schools: a system-
atic literature review. J of Palliative Med. 2007;10:229–235.
6. Plonk WM, Arnold RM. Terminal care in the last weeks of life. J Palliative
Med. 2005;8:1042–1054.
7. World Health Organisation. Cancer control: knowledge into action: WHO
guide for effective programmes: module 5: Palliative care. 2007. Available
at: http://www.who.int/cancer/media/FINAL-Palliative%20Care%20Module.
pdf. Accessed on: May 10, 2008.
8. Lorenz KA, Lynn J, Dy SM, et al. Evidence for improving palliative care at
the end of life: A systematic review. Ann Intern Med. 2008;148:147–159.
9. Dy S, Lynn J. Getting services right for those sick enough to die. BMJ.
2007;334;511–513.
10. Murray SA, Kendall M, Boyd K, et al. BMJ. 2005;330:1007–1011.
11. Glare P, Virik K, Jones M, et al. A systematic review of physicians’ survival
predictions in terminally ill cancer patients. Br Med J. 2003;327:195.
12. Stone PC, Lund S. Predicting prognosis in patients with advanced cancer.
Ann Oncol. 2007;18:971–976.
13. Christakis NA, Lamont EB. Extent and determinants of error in doctors’
prognoses in terminally ill patients: prospective cohort study. Br Med J.
2000;320:469–472.
14. Christakis NA, Escarce JJ. Survival of Medicare patients after enrollment
in hospice programs. N Engl J Med. 1996;335:172–178.
15. Hagerty RG, Butow PN, Ellis PM, et al. Communicating prognosis in
cancer care: a systematic review of the literature. Ann Oncol.
2005;16:1005–1053.
49© BMJ Publishing Group 2008
16. Barclay J, Blackhall L, Tulsky J. Communication strategies and cultural
issues in the delivery of bad news. J Palliative Med. 2007;10:958–977.
17. Pirovano M., Maltoni M, Nanni O, et al. A new palliative prognostic score: a
first step for the staging of terminally ill cancer patients. Italian Multicenter
and Study Group on Palliative Care. J Pain Symptom Manage.
1999;17:231–239.
18. Coventry PA, Grande GE, Richards DA, et al. Prediction of appropriate
timing of palliative care for older adults with non-malignant life-threatening
disease: a systematic review. Age and Aging. 2005;34:218–227.
19. Hancock K, Clayton JM, Parker SM, et al. Discrepant perceptions about
end-of-life communication: a systematic review. J Pain Symptom Manage.
2007;34:190–200.
20. The SUPPORT Principal Investigators. A controlled trial to improve care for
seriously ill hospitalized patients. The study to understand prognoses and
preferences for outcomes and risks of treatments (SUPPORT). JAMA.
1995;274:1591–1598. Erratum in: JAMA. 1996;275:1232.
21. Goodlin SJ, Hauptman PJ, Arnold R, et al. Consensus statement: Palliative
and supportive care in advanced heart failure. J Card Fail. 2004;10:200–
209.
22. Parker SM, Clayton JM, Hancock K, et al. A systematic review of
prognostic/end-of-life communication with adults in the advanced stages of
a life-limiting illness: patient/caregiver preferences for the content, style,
and timing of information. J Pain Symptom Manage. 2007;34:81–93.
23. Lorenz K, Rosenfeld K, Wenger N. Quality indicators for palliative and
end-of-life care in vulnerable elders. JAGS. 2007;55:S318-S326.
24. Knops KM, Srinivasan M, Meyers FJ. Patient desires: A model for assess-
ment of patient preferences for care of severe or terminal illness. Palliat
Support Care. 2005;3:289–299.
25. Williams A. Perspectives on spirituality at the end of life: a meta-summary.
Palliat Support Care. 2006;4;407–417.
26. Legalhelpmate. What is Patient Self Determination Act? Available at:
http://www.legalhelpmate.com/health-care-directive-patient-act.aspx.
Accessed on: May 10, 2008.
27. Shalowitz DL, Garrett-Mayer E, Wendler D. The accuracy of surrogate
decision makers: a systematic review. Arch Intern Med. 2006;166:493–
497.
28. Thomas REW. A literature review of randomized controlled trials of the
organization of care at the end of life. Can J Aging. 2006;25:271–293.
29. Johnson KS, Elbert-Avila KI, Tulsky JA. The influence of spiritual beliefs
and practices on the treatment preferences of African-Americans: a review
of the literature. J Am Geriatr Soc. 2005;53:711–719.
50 © BMJ Publishing Group 2008
30. Tang ST.When death is imminent: where terminally ill patients with cancer
prefer to die and why. Cancer Nurs. 2003;26:245–251.
31. Hays JC, Galanos AN, Palmer TA, et al. Preference for place of death in a
continuing care retirement community. Gerontologist. 2001;41:123–128.
32. Gruneir A, Mor V. Where people die: a multilevel approach to understand-
ing influences on site of death in America. Med Care Res Rev.
2007;64:351–378.
33. Center for gerontology and health care research. Policy relevant data on
care at the end of life. 2004. Available at http://www.chcr.brown.edu/dying/
usastatistics.htm. Accessed on: May 10, 2008.
34. Gomes B, Higginson IJ. Factors influencing death at home in terminally ill
patients with cancer: systematic review. BMJ. 2006;332:515–521.
35. Pritchard RS, Fisher ES, Teno JM, et al. Influence of patient preferences
and local health system characteristics on the place of death. SUPPORT
Investigators. Study to Understand Prognoses and Preferences for Risks
and Outcomes of Treatment. J Am Geriatr Soc. 1998;46:1242–1250.
36. Hudson PL, Kristjanson LJ, Ashby M, et al. Desire for hastened death in
patients with advanced disease and the evidence base of clinical guide-
lines: a systematic review. Palliative Med. 2006; 20: 693–701.
37. Burridge L, Winch S, Clavarino A. Reluctance to care: a systematic review
and development of a conceptual framework. Cancer Nurs. 2007;30:E9-
E19.
38. Cannuscio CC, Jones C, Kawachi I, et al. Reverberations of family illness:
a longitudinal assessment of informal caregiving and mental health status
in the Nurses’ Health Study. Am J Public Health. 2002;92:1305–1311.
39. Schulz R, Beach SR. Caregiving as a risk factor for mortality: The
caregiver health effects study. JAMA. 1999;282:2215–2219.
40. Harding R, Higginson IJ. What is the best way to help caregivers in cancer
and palliative care? A systematic literature review of interventions and their
effectiveness. J Palliative Med 2003;17:63–74.
41. Hebert RS, Arnold RM, Schulz R. Improving well-being in caregivers of
terminally ill patients. Making the case for patient suffering as a focus for
intervention research. J Pain Symptom Manage. 2007; 34: 539–546.
42. Jayawardena K, Liao S. Elder abuse at end of life. J Palliative Med.
2006;9:127–136.
43. McPherson CJ, Wilson KG, Murray MA. Feeling like a burden to others: a
systematic review focusing on the end of life. Palliative Med. 2007;21:115–
128.
44. Yabroff KR, Mandelblatt JS, Ingham J. The quality of medical care at the
51© BMJ Publishing Group 2008
end-of-life in the USA: existing barriers and examples of process and
outcome measures. Palliative Med. 2004;18:202–216.
45. Chibnall, JT, Bennett ML, Videen SD, et al. Identifying barriers to psycho-
social spiritual care at the end of life: a physician group study. Am J Hosp
Palliat Care. 2004;21:419–426.
46. Jacobsen R, Sjøgren P, Møldrup C, et al. Physician-related barriers to
cancer pain management with opioid analgesics: a systematic review. J
Opioid Manage. 2007;3:207–214.
47. Emanuel L, Bennett, K, Richardson, VE. The dying role. J Palliative Med.
2007;10:159–168.
48. Reid CM, Gooberman-Hill R, Hanks GW. Opioid analgesics for cancer
pain: symptom control for the living or comfort for the dying. A qualitative
study to investigate the factors influencing the decision to accept morphine
for pain caused by cancer. Ann Oncol. 2008;19:44–48.
49. Berry PH. The pain of residents with terminal cancer in USA nursing
homes: family members’ perspectives. Int J Palliative Nurs. 2007;13:20–27.
50. McCarthy EP, Burns RB, Davis RB, et al. Barriers to hospice care among
older patients dying with lung and colorectal cancer. J Clin Oncol.
2003;21:728–735.
51. Lorenz KA, Ettner SL, Rosenfeld KE, et al. Accommodating ethnic diver-
sity: a study of California hospice programs. Med Care. 2004;42:871–874.
52. Rodriguez KL, Barnato AE, Arnold RM. Perceptions and utilization of
palliative care services in acute care hospitals. J Palliative Med.
2007;10:99–110.
53. Yohannes AM. Palliative care provision for patients with chronic obstructive
pulmonary disease. Health Qual Life Outcomes. 2007;5:17.
54. Knauft E, Nielsen EL, Engelberg RA, et al. Barriers and facilitators to
end-of-life care communication for patients with COPD. Chest.
2005;127:2188–2196.
55. Sachs GA, Shega JW, Cox-Hayley D. Barriers to excellent end-of-life care
for patients with dementia. J Gen Intern Med. 2004;19:1057–1063.
56. Miovic M, Block S. Psychiatric disorders in advanced cancer. Cancer.
2007;110:1665–1676.
57. Alvarez MP. Systematic review of educational interventions in palliative
care for primary care physicians. Palliative Med. 2006;20:673–683.
58. Gorman TE, Ahern SP, Wiseman J, et al. Residents’ end-of-life decision
making with adult hospitalized patients: a review of the literature. Acad
Med. 2005;80:622–633.
52 © BMJ Publishing Group 2008
59. Frank C, Whiting N. “Get the code status:” Teaching housestaff about
end-of-life communication with older patients. Geriatrics Today: J Can
Geriatr Soc. 2004;7:6–9.
60. Fellowes D, Wilkinson S, Moore P. Communication skills training for health
care professionals working with cancer patients, their families and/or
careers. Cochrane Database of Syst Rev. 2004;2:CD003751.
61. Clayton JM, Butow PN, Tattersall MH, et al. Randomized controlled trial of
a prompt list to help advanced cancer patients and their caregivers to ask
questions about prognosis and end-of-life care. J Clin Oncol. 2007;25:715–
723.
62. Jezewski MA, Meeker MA, Sessanna L, et al. The effectiveness of
interventions to increase advance directive completion rates. J Aging
Health. 2007;19:519–536.
63. Ramsaroop SD, Reid MC, Adelman RD. Completing an advance directive
in the primary care setting: what do we need for success? J Am Geriatr
Soc. 2007;55:277–283.
64. Elbogen EB, Swanson JW, Appelbaum PS, et al. Competence to complete
psychiatric advance directives: effects of facilitated decision making. Law &
Hum Behav. 2007;31:275–289.
65. Sudore RLL. An advance directive redesigned to meet the literacy level of
most adults: A randomized trial. Patient Educ Couns. 2007;69:165–195.
66. Nicolasora N, Pannala R, Mountantonakis S, et al. If asked, hospitalized
patients will choose whether to receive life-sustaining therapies. J Hosp
Med. 2006;1:161–167.
67. Hammes BJ, Briggs LA. Initiating, facilitating, and honoring conversations
about future medical care. In: Doka KJ, Jennings B, Corr CA, eds. Ethical
dilemmas at the end of life. Washington, DC: Hospice Foundation of
America; 2005:125–138.
68. Schmidt TA, Hickman SE, Tolle SW, et al. The Physician Orders for
Life-Sustaining Treatment (POLST) program: Oregon emergency medical
technicians’ practical experiences and attitudes. J Am Geriatr Soc.
2004;52:1430–1434.
69. Lemiengre J, de Casterlé BD, Van Craen K, et al. Institutional ethics
policies on medical end-of-life decisions; a literature review. Health Policy.
2007;83:131–143.
70. Morss S. Enteral and parenteral nutrition in terminally ill cancer patients: a
review of the literature. Am J Hosp Palliat Med. 2006;23:369–377.
71. Zimmermann D, Riechelmann R, Krzyzanowska M, et al. Effectiveness of
specialized palliative care: a systematic review. JAMA. 2008;299:1698–
1709.
53© BMJ Publishing Group 2008
72. Brandsen CK. Social work and end-of-life care: reviewing the past and
moving forward. J Soc Work End Life Palliat Care. 2005;1:45–70.
73. Casarett DJ, Quill TE. “I’m not ready for hospice”: strategies for timely and
effective hospice discussions. Ann Intern Med. 2007;146:443–449.
74. Wilson DM, Justice C, Thomas R, et al. End-of-life care volunteers: a
systematic review of the literature. Health Serv Manage Res.
2005;18:244–257.
75. Au D, Udris E, Fihn S, et al. Differences in health care utilization at the end
of life among patients with chronic obstructive pulmonary disease and
patients with lung cancer. Arch Intern Med. 2006;166:326–331.
76. Saxby C, Ackroyd R, Callin S, et al. How should we measure emesis in
palliative care? Palliative Med. 2007;21:369–383.
77. Nekolaichuk C, Watanabe S, Beaumont C. The Edmonton Symptom
Assessment System: a 15-year retrospective review of validation studies
(1991–2006). Palliat Med. 2008;22:111–122.
78. Tranmer JE, Heyland D, Dudgeon D, et al. Measuring the symptom
experience of seriously ill cancer and noncancer hospitalized patients near
the end of life with the memorial symptom assessment scale. J Pain
Symptom Manage. 2003;25:420–429.
79. TIME: Toolkit of instruments to measure end-of-life care. About the Toolkit.
2004. Available at: http://www.chcr.brown.edu/pcoc/toolkit.htm. Accessed
on: May 10, 2008.
80. Mularski RA, Dy SM, Shugarman LR, et al. A systematic review of
measures of end-of-life care and its outcomes. Health Services Res.
2007;42:1848–1870.
81. City of Hope Pain and Palliative Care Resource Center. 2008. Available at:
http://www.cityofhope.org/prc/. Accessed on: May 10, 2008.
82. Lorenz KA, Lynn J. Cancer care quality measures: symptoms and end of
life care. Evidence Report/Technology Assessment. 2006;137:1–77.
83. Teunissen SCCM, Wesker W, Kruitwagen C, et al. Symptom prevalence in
patients with incurable cancer: a systematic review. J Pain Symptom
Manage. 2007;34:94–104.
84. Solano JP, Gomes B, Higginson IJ. A comparison of symptom prevalence
in far advanced cancer, AIDS, heart failure, chronic obstructive pulmonary
disease, and renal disease. J Pain Symptom Manage. 2006;31:58–69.
85. Holen JC, Polit C, Hjermstad MJ, et al. Pain assessment tools: is the
content appropriate for use in palliative care? J Pain Symptom Manage.
2006;32:567–580.
54 © BMJ Publishing Group 2008
86. TIME: Toolkit of instruments to measure end-of-life care. Pain and physical
symptoms. 2004. Available at: http://www.chcr.brown.edu/pcoc/Physical.
htm. Accessed on: May 10, 2008.
87. Pautex S, Herrmann F, Le Lous P, et al. Feasibility and reliability of four
pain self-assessment scales and correlation with an observational rating
scale in hospitalized elderly demented patients. J Gerontol A Biol Sci Med
Sci. 2005;60A:524–529.
88. City of Hope. Pain and symptom management: Pain assessment tools.
2008. Available at http://www.cityofhope.org/prc/pain_assessment.asp.
Accessed on: May 10, 2008.
89. Pace MC, Passavanti MB, Grella E. Buprenorphine in long-term control of
chronic pain in cancer patients. Front Biosci. 2007;12:1291–1299.
90. Quigley C. The role of opioids in cancer pain. BMJ. 2005;331:825–829.
91. Fine PG. The evolving and important role of anesthesiology in palliative
care. Anesth Analg. 2005;100:183–188.
92. Marinangeli F, Ciccozzi A, Leonardis M. Use of strong opioids in advanced
cancer pain: a randomised trial. J Pain Symptom Manage. 2004;27:409–
416.
93. Wiffen PJ, McQuay HJ. Oral morphine for cancer pain.Cochrane Database
Syst Rev. 2007;4:CD003868.
94. Quigley C. Opioids in people with cancer-related pain. BMJ Clinical
Evidence 2008 (in press).
95. Davis MP, Weissman DE, Arnold RM. Opioid dose titration for severe
cancer pain: A systematic evidence-based review. J Palliative Med.
2004;7:462–468.
96. Zeppetella G, Ribeiro MDC. Opioids for the management of breakthrough
pain in cancer patients. Cochrane Database Syst Rev. 2006;1:CD004311.
97. Slatkin NE, Xie F, Messina J, et al. Fentanyl buccal tablet for relief of
breakthrough pain in opioid-tolerant patients with cancer-related chronic
pain. J Support Oncol. 2007;5:327–334.
98. FDA. FDA warns of potential serious side effects with breakthrough cancer
pain drug. 2007. Available at http://www.fda.gov/bbs/topics/NEWS/2007/
NEW01711.html. Accessed on: May 10, 2008.
99. Anderson SL, Shreve ST. Continuous subcutaneous infusion of opiates at
end-of-life. Ann Pharmacother. 2004;38:1015–1023.
100. Ballantyne JC, Carwood CM. Comparative efficacy of epidural, subarach-
noid, and intracerebroventricular opioids in patients with pain due to
cancer. Cochrane Database Syst Rev. 2005;2:CD005178.
101. Grosset AB, Roberts MS, Woodson ME, et al. Comparative efficacy of oral
extended-release hydromorphone and immediate-release hydromorphone
55© BMJ Publishing Group 2008
in patients with persistent moderate to severe pain: two randomized
controlled trials. J Pain Symptom Manage. 2005;29:584–594.
102. Reid CMM. Oxycodone for cancer-related pain: Meta-analysis of rand-
omized controlled trials. Arch Intern Med. 2006;166:837–843.
103. Nicholson AB. Methadone for cancer pain. Cochrane Database Syst Rev.
2007;4:CD003971.
104. McNicol E, Strassels SA, Goudas L, et al. NSAIDS or paracetamol, alone
or combined with opioids, for cancer pain. Cochrane Database Syst Rev.
2005;2:CD005180.
105. Gøtzsche P. NSAIDs. BMJ Clinical Evidence. 2007. Available at:
http://clinicalevidence.bmj.com/ceweb/conditions/msd/1108/1108.jsp.
Accessed on: May 10, 2008.
106. Mercadante S, Fulfaro F, Casuccio A. A randomised controlled study on
the use of anti-inflammatory drugs in patients with cancer pain on
morphine therapy: effects on dose-escalation and a pharmacoeconomic
analysis. Eur J Cancer. 2002;38:1358–1363.
107. Axelsson B, Borup S. Is there an additive analgesic effect of paracetamol
at step 3? A double-blind randomized controlled study. Palliative Med.
2003;17:724–725.
108. Rodriguez RF, Castillo JM, Del Pilar Castillo M. Codeine/acetaminophen
and hydrocodone/acetaminophen combination tablets for the management
of chronic cancer pain in adults: a 23-day, prospective, double-blind,
randomized, parallel-group study. Clin Therapeutics. 2007;29:581–587.
109. Gooch K, Culleton BF, Manns BJ, et al. NSAID use and progression of
chronic kidney disease. Am J Med 2007;120:280.e1–7.
110. Mercadante SL, Berchovich M, Casuccio A. A prospective randomized
study of corticosteroids as adjuvant drugs to opioids in advanced cancer
patients. Am J Hosp Palliat Care. 2007;24:13–19.
111. Bell RF, Eccleston C, Kalso E. Ketamine as an adjuvant to opioids for
cancer pain. J Pain Symptom Manage. 2003;26:867–875.
112. Yan BM, Myers RP. Neurolytic celiac plexus block for pain control in
unresectable pancreatic cancer. Am J Gastroenterol. 2007;102:430–438.
113. Süleyman Ozyalçin N, Talu GK, Camlica H, et al. Efficacy of coeliac plexus
and splanchnic nerve blockades in body and tail located pancreatic cancer
pain. Eur J Pain. 2004;8:539–545.
114. Saarto T, Wiffen PJ. Antidepressants for neuropathic pain. Cochrane
Database Syst Rev. 2007;4:CD005454.
115. Finnerup NB, Otto M, Jensen TS, et al. An evidence-based algorithm for
the treatment of neuropathic pain. Med Gen Med. 2007; 9: 36.
56 © BMJ Publishing Group 2008
116. Wiffen PJ, Rees J. Lamotrigine for acute and chronic pain. Cochrane
Database Syst Rev. 2007;2:CD006044.
117. Keskinbora K, Pekel AF, Aydinli I. Gabapentin and an opioid combination
versus opioid alone for the management of neuropathic cancer pain: a
randomized open trial. J Pain Symptom Manage. 2007;34:183–189.
118. Eisenberg E, McNicol E, Carr DB. Opioids for neuropathic pain. Cochrane
Database Syst Rev. 2006;3:CD006146.
119. Hans G. Buprenorphine: a review of its role in neuropathic pain. J Opioid
Manage. 2007;3:195–206.
120. Challapalli V, Tremont-Lukats IW, McNicol ED. Systemic administration of
local anesthetic agents to relieve neuropathic pain. Cochrane Database
Syst Rev. 2005;4:CD003345.
121. Mailis-Gagnon A, Furlan AD, Sandoval JA, et al. Spinal cord stimulation for
chronic pain. Cochrane Database Syst Rev. 2004:3:CD003783.
122. Devine EC, Westlake SK. The effects of psychoeducational care provided
to adults with cancer: meta-analysis of 116 studies. Oncol Nurs Forum.
1995;22:1369–1381.
123. Dalton JA, Keefe FJ, Carlson J, et al. Tailoring cognitive-behavioral
treatment for cancer pain. Pain Management Nursing. 2004;5:3–18.
124. Given C, Given B, Rahbar M, et al. Effect of a cognitive behavioral
intervention on reducing symptom severity during chemotherapy. J Clin
Oncol. 2004;22:507–516. Available at:
http://jco.ascopubs.org/cgi/content/full/22/3/507?ck=nck. Accessed on:
May 10, 2008.
125. Tatrow K, Montgomery GH. Cognitive behavioral therapy techniques for
distress and pain in breast cancer patients: a meta-analysis. J Behavioral
Med. 2006;29:17–27.
126. McDonald MV, Pezzin LE, Feldman PH, et al. Can just in time, evidence-
based “reminders” improve pain management among home health care
nurses and their patients? J Pain Symptom Manage. 2005;29:474–488.
127. Dy GK, Bekele L, Hanson LJ, et al. Complementary and alternative
medicine use by patients enrolled onto phase I clinical trials. J Clin Oncol.
2004;22:4810–4815. Erratum in: J Clin Oncol. 2005;23:248.
128. Hlubocky FJ, Ratain MJ, Wen M, et al. Complementary and alternative
medicine among advanced cancer patients enrolled on phase I trials: a
study of prognosis, quality of life, and preferences for decision making. J
Clin Oncol. 2007;25:548–554.
129. Fellowes D, Barnes K, Wilkinson S. Aromatherapy and massage for
symptom relief in patients with cancer. Cochrane Database Syst Rev.
2004;3:CD002287.
57© BMJ Publishing Group 2008
130. Bardia A, Barton DL, Prokop LJ, et al. Efficacy of complementary and
alternative medicine therapies in relieving cancer pain: a systematic
review. J Clin Oncol. 2006;24:5457–5464.
131. Stephenson NL, Swanson M, Dalton J, et al. Partner-delivered reflexology:
effects on cancer pain and anxiety. Oncol Nurs Forum. 2007;34:127–132.
Available at: http://ons.metapress.com/content/k477114620185x62/fulltext.
html. Accessed on: May 10, 2008.
132. Tsai PS, Chen PL, Lai YL, et al. Effects of electromyography biofeedback-
assisted relaxation on pain in patients with advanced cancer in a palliative
care unit. Cancer Nurs. 2007;30:347–353.
133. Xu L, Lao LX, Ge A, et al. Chinese herbal medicine for cancer pain.
Integrative Cancer Ther. 2007;6:208–234.
134. Finlay I, Mason M, Shelley M. Radioisotopes for the palliation of metastatic
bone cancer: a systematic review. Lancet Oncol. 2005;6:392–400.
135. Serafini AN. Therapy of metastatic bone pain. J Nuclear Med.
2001;42:895–906.
136. Mystakidou K, Katsouda E, Kouloulias V, et al. Comparison of transdermal
fentanyl with codeine/paracetamol, in combination with radiotherapy, for
the management of metastatic bone pain. J Opioid Manage. 2005;1:204–
210.
137. Chow E, Harris K, Fan G, et al. Palliative radiotherapy trials for bone
metastases: a systematic review. J Clin Oncol. 2007;25:1423–1436.
138. Bauman G, Charette M, Reid R, et al. Radiopharmaceuticals for the
palliation of of painful metastasis: a systematic review. Radiotherapy
Oncol. 2005;75:258–270.
139. Wong R, Wiffen PJ. Bisphosphonates for the relief of pain secondary to
bone metastases. Cochrane Database of Syst Rev. 2002;2:CD002068.
140. Diel IJ, BodyJJ, Lichinitser MR, et al. Improved quality of life after
long-term cancer treatment with the biphosphonate ibandronate in patients
with metastatic bone disease due to breast cancer. Eur J Cancer.
2004;40;1704–1712.
141. Yuen KK, Shelley M, Sze WM, et al. Biphosphonates for advanced prostate
cancer. Cochrane Database Syst Rev. 2006;4:CD006250.
142. Liapi E, Geschwind JF. Transcatheter and ablative therapeutic approaches
for solid malignancies. J Clin Oncol. 2007;25:978–986.
143. Goetz MP, Callstrom MR, Charboneau JW, et al. Percutaneous image-
guided radiofrequency ablation of painful metastases involving bone: a
multicenter study. J Clin Oncol. 2004;22:300–306.
58 © BMJ Publishing Group 2008
144. Wood RND. Encyclopedia of cancer: calcitonin. Available at: http://
findarticles.com/p/articles/mi_gGEC/is_0010/ai_2699001073. Accessed
on: May 10, 2008.
145. Martinez-Zapata MJ, Roque M, Alonso Coello P, et al. Calcitonin for
metastatic bone pain. Cochrane Database Syst Rev. 2006;3:CD003223.
146. Kalso E, Edwards JE, Moore RA, et al. Opioids in chronic non-cancer pain:
a systematic review of efficacy and safety. Pain. 2004;112:372–380.
147. Booth S, Wade R, Johnson M, et al. The use of oxygen in the palliation of
breathlessness. A report of the expert working group of the Scientific
Committee of the Association of Palliative Medicine; Expert Working Group
of the Scientific Committee of the Association of Palliative Medicine Respir
Med. 2004;98:66–77.
148. Roberts DK, Thorne SE, Pearson C. The experience of dyspnea in
late-stage cancer. Patients and nurses’ perspectives. Cancer Nurs.
1993;16:310–320.
149. Dorman S, Byrne A, Edwards A. Which measurement scales should we
use to measure breathlessness in palliative care? A systematic review.
Palliat Med. 2007;21:177–191.
150. Bausewein C, Farquhar M, Booth S, et al. Measurement of breathlessness
in advanced disease: a systematic review. Resp Med. 2007;101:399–410.
151. Bruera E, Sweeney C, Willey J, et al. A randomized controlled trial of
supplemental oxygen versus air in cancer patients with dyspnea. Palliat
Med. 2003;17:659–663.
152. Gallagher R, Roberts DA. Systematic review of oxygen and airflow effect
on relief of dyspnea at rest in patients with advanced disease of any
cause. J Pain Palliat Care Pharmacother. 2004;18:3–15.
153. Booth S, Moosavi SH, Higginson IJ. The etiology and management of
intractable breathlessness in patients with advanced cancer: a systematic
review of pharmacological therapy. Nat Clin Pract Oncol. 2008;5:90–100.
154. Jennings AL, Davies AN, Higgins JP, et al. A systematic review of the use
of opioids in the management of dyspnoea. Thorax. 2002;57:939–944.
155. Abernethy AP, Currow DC, Frith P, et al. Randomised double blind
controlled crossover trial of sustained release morphine for the manage-
ment of refractory dyspnoea. BMJ. 2003;327:523–528.
156. Navigante AH, Cerchietti LCA, Castro MA, et al. Midazolam as adjunct
therapy to morphine in the alleviation of severe dyspnea perception in
patients with advanced cancer. J Pain Symptom Manage. 2006;31:38–47.
157. Salman GF, Mosier MC, Beasley BW, et al. Rehabilitation for patients with
chronic obstructive pulmonary disease: meta-analysis of randomized con-
trolled trials. J Gen Intern Med. 2003;18:213–221.
59© BMJ Publishing Group 2008
158. Pan CX, Morrison RS, Ness J, et al. Complementary and alternative
medicine in the management of pain, dyspnea, and nausea and vomiting
near the end of life. A systematic review. J Pain Symptom Manage.
2000;20:374–387.
159. Lewith GT, Prescott P, Davis CL. Can a standardised acupuncture tech-
nique palliate disabling breathlessness: a single-blind, placebo controlled
crossover study. Chest. 2004;125:1783–1790.
160. Vickers AJF. Acupuncture for dyspnea in advanced cancer: a randomized,
placebo-controlled pilot trial [ISRCTN89462491]. BMC Palliative Care.
2005;4:5.
161. Lester JF, Macbeth FR, Toy E, et al. Palliative radiotherapy regimens for
non small cell lung cancer. Cochrane Database Syst Rev.
2006;4:CD002143.
162. Lutz S, Chow E, Hartsell A, et al. A review of hypofractionated palliative
radiotherapy. Cancer. 2007;109:1462–1470.
163. Ung YC, Yu E, Falkson C, et al. The role of radiation therapy in malignant
pleural mesothelioma: A systematic review. Radiotherapy Oncol.
2006;80:13–18.
164. Shaw P, Agarwal R. Pleurodesis for malignant pleural effusions. Cochrane
Database Syst Rev. 2004;1:CD002916.
165. Ukale V, Agrenius V, Hillerdal G, et al. Pleurodesis in recurrent pleural
effusions: a randomized comparison of a classical and a currently popular
drug. Lung Cancer. 2004;43:323–328.
166. Goodman A, Davies CW. Efficacy of short-term versus long-term chest
tube drainage following talc slurry pleurodesis in patients with malignant
pleural effusions: a randomised trial. Lung Cancer. 2006;54:51–55.
167. Dresler CM, Olak J, Herndon JE, et al. Phase III intergroup study of talc
poudrage vs talc slurry sclerosis for malignant pleural effusion. Chest.
2005;127:909–915.
168. Crnjac A, Sok M, Kamenik M. Impact of pleural effusion pH on the efficacy
of thoracoscopic mechanical pleurodesis in patients with breast
carcinoma. Eur J Cardiothoracic Surg. 2004;26:432–436.
169. Sartori S, Tassinari D, Ceccotti P, et al. Prospective randomized trial of
intrapleural bleomycin versus interferon alfa-2b via ultrasound-guided
small-bore chest tube in the palliative treatment of malignant pleural
effusions. J Clin Oncol. 2004;22:1228–1233.
170. Mota DDCF, Pimenta CAM. Self-report instruments for fatigue assess-
ment: a systematic review. Res Theory Nurs Pract. 2006;20:49–78.
171. Mitchell SA, Berger AM. Cancer-related fatigue: the evidence base for
assessment and management. Cancer J. 2006;12:374–387.
60 © BMJ Publishing Group 2008
172. Prue G, Rankin J, Allen J, et al. Cancer-related fatigue: a critical appraisal.
Eur J Cancer. 2006;42:846–863.
173. Jacobsen PB, Donovan KA, Vadaparampil ST, et al. Systematic review and
meta-analysis of psychological and activity-based interventions for cancer-
related fatigue. Health Psychol. 2007;26:660–667.
174. Ream E, Richarson A, Dann C. Supportive intervention for fatigue in
patients undergoing chemotherapy: a randomized controlled trial. J Pain
Symptom Manage. 2006;31:148–161.
175. Cramp F, Daniel J. Exercise for the management of cancer-related fatigue
in adults. Cochrane Database Syst Rev. 2008:2:CD006145.
176. Lee MS, Pittler MH, Ernst E. Is Tai Chi an effective adjunct in cancer care?
A systematic review of controlled clinical trials. Supportive Care in Cancer.
2007:15:597–601.
177. Lee MS, Chen KW, Sancier KM, et al. Quigong for cancer treatment: a
systematic review of controlled clinical trials. Acta Oncologica.
2007;46:717–722.
178. Radbruch L, Strasser F, Elsner F, et al. and the Research Steering
Committee of the European Association for Palliative Care (EAPC).
Fatigue in palliative care patients—an EAPC approach. Palliat Med.
2008;22:13–32.
179. Minton O, Stone P, Richardson A, et al. Drug therapy for the management
of cancer related fatigue. Cochrane Database Syst Rev.
2008;1:CD006704.
180. Butler JM Jr, Case LD, Atkins J, et al. A phase III double-blind, placebo-
controlled prospective randomized clinical trial of d-threo-methylphenidate
HCL in brain tumor patients receiving radiation therapy. Int J Radiat Oncol
Biol Phys. 2007;69:1496–1501.
181. FDA. Ritalin LA. 2007. Available at: http://www.fda.gov/medwatch/safety/
2007/Apr_PI/RitalinLA_PI.pdf. Accessed on: May 10, 2008.
182. Sood A, Barton DL, Bauer BA, et al. A critical review of complementary
therapies for cancer-related fatigue. Integr Cancer Ther. 2007;6:8–13.
183. FDA. Additional trials showing increased mortality and/or tumor progres-
sion with EPOGEN®/PROCRIT® and Aranesp®. 2008. Available at: http://
www.fda.gov/medwatch/safety/2008/epo_DHCP_03102008.pdf. Accessed
on: May 10, 2008.
184. Berger AM, Sankaranarayanan J, Watanabe-Galloway S, et al. Current
methodological approaches to the study of sleep disturbances and quality
of life in adults with cancer: a systematic review. Psycho-Oncology.
2007;16:401–420.
185. Savard J, Simard S, Ivers H. et al. Randomized study on the efficacy of
61© BMJ Publishing Group 2008
cognitive-behavioral therapy for insomnia secondary to breast cancer, part
I: sleep and psychological effects. J Clin Oncol. 2005;23:6083–6096.
186. Block SD, Block SD. Psychological issues in end-of-life care. J Palliative
Med. 2006;9:751–772.
187. Ryan H, Schofield P, Cockburn J, et al. How to recognize and manage
psychological distress in cancer patients. Eur J Cancer Care. 2005;14:7–
15.
188. Jackson KC, Lipman AG. Drug therapy for anxiety in palliative care.
Cochrane Database Syst Rev. 2004;1:CD004596.
189. Rodin G, Lloyd N, Katz M, et al. The treatment of depression in cancer
patients: a systematic review. Supportive Care in Cancer. 2007;15:123–
136.
190. Stockler MR, O’Connell R, Nowak AK, et al. Effect of sertraline on
symptoms and survival in patients with advanced cancer, but without major
depression: a placebo-controlled double-blind randomised trial. Lancet
Oncol. 2007;8:603–612.
191. Lacasse Y, Beaudoin L, Rousseau L, et al. Randomized trial of paroxetine
in end-stage COPD. Arch Chest Dis. 2004;61:140–147.
192. Uitterhoeve RJ, Vernooy M, Litjens M, et al. Psychosocial interventions for
patients with advanced cancer – A systematic review of the literature. Br J
Cancer. 2004;91:1050–1062.
193. Sherwood P, Given BA, Given CW, et al. A cognitive behavioral interven-
tion for symptom management in patients with advanced cancer. Oncol
Nurs Forum. 2005;32:1190–1198.
194. Savard J, Simard S, Giguere I, et al. Randomized clinical trial on cognitive
therapy for depression in women with metastatic breast cancer: psycho-
logical and immunological effects. Palliative Supportive Care. 2006;4:219–
237.
195. Smith JE, Richardson J, Hoffman C, et al. Mindfulness-Based Stress
Reduction as supportive therapy in cancer care: systematic review. J Adv
Nurs. 2005;52:315–327.
196. Monti DA, Peterson C, Kunkel EJ, et al. A randomized, controlled trial of
mindfulness-based art therapy (MBAT) for women with cancer. Psycho-
Oncology. 2006;15:363–373.
197. Thomas R, Wilson D. Randomized controlled trials of non-medical and
non-surgical therapies for palliative care: a literature review. Alt Med Rev.
2005;10:204–215.
198. Wilkinson SM, Love SB, Westcombe AM, et al. Effectiveness of aroma-
therapy massage in the management of anxiety and depression in patients
with cancer: a multicenter randomized controlled trial. J Clin Oncol.
2007;25:532–539.
62 © BMJ Publishing Group 2008
199. Wilcock A, Manderson C, Weller R, et al. Does aromatherapy massage
benefit patients with cancer attending a specialist palliative care day
centre? Palliat Med. 2004;18:287–290.
200. Williams AL, Selwyn PA, Liberti L, et al. A randomized controlled trial of
meditation and massage effects on quality of life in people with late-stage
disease: a pilot study. J Palliative Med. 2005;8:939–952.
201. Soden K, Vincent K, Craske S, et al. A randomized controlled trial of
aromatherapy massage in a hospice setting. Palliat Med. 2004;18:87–92.
202. Hilliard RE. Music therapy in hospice and palliative care: a review of the
empirical data. Evid Based Complement Alternat Med. 2005;2:173–178.
203. Dileo C. Effects of music and music therapy on medical patients: A
meta-analysis of the research and implications for the future. J Soc
Integrative Oncol. 2006;4:67–70.
204. Hanser SB, Bauer Wu S, Kubicek L, et al. Effects of a music therapy
intervention on quality of life and distress in women with metastatic breast
cancer. J Soc Integrative Oncol. 2006;4:116–124.
205. Stephenson NL, Swanson M, Dalton J, et al. Partner-delivered reflexology:
effects on cancer pain and anxiety. Oncol Nurs Forum. 2007;34:127–132.
206. Milazzo S, Russell N, Ernst E. Efficacy of homeopathic therapy in cancer
treatment. Eur J Cancer. 2006;42:282–289.
207. Roffe L, Schmidt K, Ernst E. A systematic review of guided imagery as an
adjuvant cancer therapy. Psychooncology. 2005;14:607–617.
208. Cruickshank S, Kennedy C, Lockhart K, et al. Specialist breast care nurses
for supportive care of women with breast cancer. Cochrane Database Syst
Rev. 2008;1: CD005634.
209. Young J, Inouye SK. Delirium in older people. BMJ. 2007;334:842–846.
210. Leslie DL, Zhang Y, Holford TR, et al. Premature death associated with
delirium at 1-year follow-up. Arch Intern Med. 2005;165:1657–1662.
211. Caraceni A, Nanni O, Maltoni M, et al. Impact of delirium on the short term
prognosis of advanced cancer patients. Cancer. 2000;89:1145–1149.
212. Bruera E, Miller L, McCallion J, et al. Cognitive failure in patients with
terminal cancer: a prospective study. J Pain Symptom Manage.
1992;7:192–195.
213. Centeno C, Sanz Á, Bruera E. Delirium in advanced cancer patients. Palliat
Med. 2004;18:184–194.
214. Inouye SK, van Dyck CH, Alessi CA, et al. Clarifying confusion: the
confusion assessment method. A new method for detection of delirium.
Ann Intern Med. 1990;113:941–948.
63© BMJ Publishing Group 2008
215. Breitbart W, Rosenfeld B, Roth A, et al. The Memorial Delirium Assess-
ment Scale. JPSM. 1997;13:128–137.
216. Inouye SK. A multicomponent intervention to prevent delirium in hospital-
ized older patients. N Engl J Med. 1999;340;669–676.
217. Inouye SK, Bogardus ST, Baker DI, et al. The hospital elder life program: a
model of care to prevent cognitive and functional decline in hospitalized
older patients. J Am Geriatr Soc. 2000:48:1697–1706.
218. Quigley C. Opioid switching to improve pain relief and drug tolerability.
Cochrane Database Syst Rev. 2004:3:CD004847.
219. Mercadante S, Bruera E. Opioid switching: a systematic and critical review.
Cancer Treat Rev. 2006;32:304–315.
220. Indelicato RA, Portenoy RK. Opioid rotation in the management of refrac-
tory cancer pain. J Clin Oncol. 2002;20:348–352.
221. Michaud L, Büla C, Berney A, et al. Delirium: Guidelines for general
hospitals. J Psychosomatic Res. 2007;62:371–383.
222. Lonergan E, Britton AM, Luxenberg J, et al. Antipsychotics for delirium.
Cochrane Database Syst Rev. 2007;2:CD005594.
223. Warner J, Butler R, Wuntakal B. Dementia. BMJ Clinical Evidence. 2006.
Available at:
http://clinicalevidence.bmj.com/ceweb/conditions/meh/1001/1001.jsp.
Accessed on: May 10, 2008.
224. Wooltorton E. Risperidone(Risperdal):Increased rate of cerebrovascular
events in dementia trials. CMAJ. 2002;167:1269–1270.
225. Wooltorton E. Olanzapine (Zyprexa): Increased incidence of cerebrovascu-
lar events in clinical trials. CMAJ. 2004;170:1395.
226. FDA. Atypical antipsychotic drugs information. 2006. Available at: http://
www.fda.gov/cder/drug/infopage/antipsychotics/default.htm. Accessed on:
May 10, 2008.
227. Jackson KC, Lipman AG. Drug therapy for delirium in terminally ill patients.
Cochrane Database Syst Rev. 2004;2:CD004770.
228. Breitbart W, Rocco M, Platt MM, et al. A double-blind of haloperidol,
chlorpromazine, and lorazepam in the treatment of delirium in hospitalized
AIDS patients. Am J Psychiatry. 1996;153:231–237.
229. Yavuzsen T, Davis MP, Walsh D, et al. Systematic review of the treatment of
cancer-associated anorexia and weight loss. J Clin Oncol. 2005;23:8500–
8511.
230. Couch M, Lai V, Cannon T, et al. Cancer cachexia syndrome in head and
neck cancer patients: part I. Diagnosis, impact on quality of life and
survival, and treatment. Head Neck. 2007;29:401–411.
64 © BMJ Publishing Group 2008
231. Moses AW, Slater C, Preston T, et al. Reduced total energy expenditure
and physical activity in cachectic patients with pancreatic cancer can be
modulated by an energy and protein dense oral supplement enriched with
n-3 fatty acids. Br J Cancer. 2004;90:996–1002.
232. Berenstein EG, Ortiz Z. Megestrol acetate for treatment of anorexia-
cachexia syndrome. Cochrane Database Syst Rev. 2005;2:CD004310.
233. Bodenner D, Spencer T, Riggs AT, et al. A retrospective study of the
association between megestrol acetate administration and mortality
among nursing home residents with clinically significant weight loss. Am J
Geriatr Pharmacother. 2007;5:137–146.
234. Koretz RL, Avenell A, Lipman TO, et al. Does enteral nutrition affect clinical
outcome? A systematic review of the randomized trials. Am J
Gastroenterol. 2007;102:412–429.
235. Shang E, Weiss C, Post S, et al. The influence of early supplementation of
parenteral nutrition on quality of life and body composition in patients with
advanced cancer. J Parenteral Enteral Nutr. 2006; 30:222–230.
236. Lundholm K, Daneryd P, Bosaeus I, et al. Palliative nutritional intervention
in addition to cyclooxygenase and erythropoietin treatment for patients
with malignant disease: effects on survival, metabolism, and function.
Cancer. 2004;100:1967–1977.
237. Lanuke K, Fainsinger RL. Hydration management in palliative care set-
tings: a survey of experts. J Palliat Care 2003;19:278–279.
238. McCann RM, Hall WJ, Groth-Juncker A. Comfort care for terminally ill
patients. The appropriate use of nutrition and hydration. JAMA.
1994;272:1263–1266.
239. van der Riet P, Good P, Higgins I, et al. Palliative care professionals’
perceptions of nutrition and hydration at the end of life. Int J Palliat Nurs.
2008;14:145–151.
240. Morita T, Tei Y, Tsunoda J, et al. Determinants of the sensation of thirst in
terminally ill cancer patients. Support Care Cancer. 2001;9:177–186.
241. Good P, Cavenagh J, Mather M, et al. Medically assisted hydration for
palliative care patients. Cochrane Database Syst Rev. 2008:2:CD006273.
242. Grunberg SM. Antiemetic activity of corticosteroids in patients receiving
cancer chemotherapy: dosing, efficacy, and tolerability analysis. Ann
Oncol. 2007;18:233–240.
243. Hallenbeck J. Fast fact and concepts #5: causes of nausea and vomiting.
2005. Available at: http://www.eperc.mcw.edu/fastFact/ff_005.htm.
Accessed on: May 10, 2008.
244. Clemens KE, Klaschik E. Managing nausea, emesis, and constipation in
palliative care. Dtsch Arztebl. 2007;104:A269-A278.
65© BMJ Publishing Group 2008
245. Pancha SJ, Muller-Schwefe J, Wurzelmann JI. Opioid-induced bowel
dysfunction: prevalence, pathophysiology and burden. J Clin Pract.
2007;61:1181–1187.
246. Miles CL, Fellowes D, Goodman ML, et al. Laxatives for the management
of constipation in palliative care patients. Cochrane Database Syst Rev.
2006:4:CD003448.
247. Ramesh P, Suresh Kumar K, Rajagopal M, et al. Managing morphine-
induced constipation: a controlled comparison of the ayurvedic formulation
and senna. J Pain Symptom Manage. 1998;16:240–244.
248. Hurdon V, Viola R, Schroder C. How useful is ducosate in patients at risk
for constipation? A systematic review of the evidence in the chronically ill.
J Pain Symptom Manage. 2000;19:130–136.
249. Ohlen K. The effect of polyethylene glycol in chronic constipation is not
sufficiently evaluated. A systematic literature review. Lakartidningen.
2004;101:2568–2572.
250. Van Der Spoel JIO, Zandstra DFV. Laxation of critically ill patients with
lactulose or polyethylene glycol: A two-center randomized, double-blind,
placebo-controlled trial. Crit Care Med. 2007;35:2726–2731.
251. Mendoza J, Legido J, Rubio S, et al. Systematic review: The adverse
effects of sodium phosphate enema. Aliment Pharmacol Ther.. 2007:26:9–
20.
252. Becker G, Galandi F, Blum HE. Peripherally acting opioid antagonists in the
treatment of opiate-related constipation: a systematic review. J Pain
Symptom Manage. 2007;34:547–565.
253. Yuan CS. Methylnaltrexone mechanisms of action and effects on opioid
bowel dysfunction and other opioid adverse effects. Ann Pharmacother.
2007;41:984–993.
254. FDA. FDA approves Relistor for opioid-induced constipation. 2008. Avail-
able at: http://www.fda.gov/bbs/topics/NEWS/2008/NEW01826.html.
Accessed on: May 15, 2008.
255. Morrison RS, Meier DE. Palliative care. N Engl J Med. 2004;350:2582–
2590.
256. Arnold R, Back T. Discussing prognosis. J Clin Oncol. 2006;24:4209–4213.
Available at: http://www.jco.ascopubs.org/cgi/content/full/24/25/4209.
Accessed on: May 10, 2008.
257. Bruera E, Palmer JL, Pace E, et al. A randomized, controlled trial of
physician postures when breaking bad news to cancer patients. Palliat
Med. 2007;21:501–505.
258. Strasser F, Palmer JL, Willey J, et al. Impact of physician sitting versus
standing during inpatient oncology consultations: patients’ preference and
66 © BMJ Publishing Group 2008
perception of compassion and duration. A randomized controlled trial. J
Pain Symptom Manage. 2005;29:489–497.
259. Schofield P, Carey M, Love A, et al. ‘Would you like to talk about your future
treatment options’? Discussing the transition from curative cancer treat-
ment to palliative care. Palliat Med. 2006;20:397–406.
67© BMJ Publishing Group 2008
APPENDIX A: METHODOLOGY
In this paper, we present the results of a systematic review (SR) on the
effectiveness of palliative care interventions among adults. For the searches
and literature appraisal, we adapted the search and appraisal methodology of
BMJ Clinical Evidence reviews as described at http://www.clinicalevidence.com/
ceweb/about/search_process.jsp. We included the best evidence available,
focusing on SRs and randomized controlled trials (RCTs) for the effectiveness
of interventions. We focused on studies conducted in a end-of-life context
(indicated by for example, life expectancy less than 6 months, advanced cancer
or terminal chronic disease). We extracted information from trials on the type
and quality of evidence, study population, interventions, and reported results for
our outcomes of interest (mainly quality-of-life or symptom-based clinical
outcomes, not mortality/survival).
Our searches and the initial critical appraisal were conducted by an information
specialist, and the second-round appraisal was performed by members of our
editorial team. We eclipsed superseded SRs and studies identified by included
SRs. The evidence syntheses on communication and symptom management
were based on detailed evidence summaries provided by specifically trained
editorial staff. The quality ratings of the evidence were based on the work of the
GRADE working group, adapted from the method used for reviews on BMJ
Clinical Evidence as described at http://clinicalevidence.bmj.com/ceweb/about/
about-grade.jsp.
Challenges of conducting research in end-of-life care
There are particular challenges to conducting primary research in palliative
care. These include difficulties in recruitment and retention in trials and a lack of
funding for research in this area. We also found that some systematic reviews
gave insufficient information on evidence synthesis for their methods to be
reproducible. Despite this the evidence base is improving and we hope this
report contributes to an understanding of the current state of research.
Our approach
Between December 2007 and February 2008, we searched the following
databases to identify studies relevant to palliative/end-of-life care for this
systematic review: MEDLINE and EMBASE; The Cochrane Database of Sys-
tematic Reviews and Cochrane Central Register of Controlled Clinical Trials; the
Database of Abstracts of Reviews of Effects (DARE), and the Health Tech-
nology Assessment (HTA) database. PsycINFO was also searched for citations
on delirium. Results were limited to citations of SRs or RCTs published in
English, German or Hungarian, with SR publication/RCT database entry dates
from 2004. We chose a search date of 2004 as a cut-off point as we were
building on the excellent work of the high-quality review on end-of-life care and
outcomes prepared for the Agency for Healthcare Research and Quality.1 We
did not apply date or language restrictions for searches on opioids and cancer
pain, constipation in people prescribed opioids, and delirium. For interventions
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for constipation in people prescribed opioids, and for nausea and vomiting, we
also carried out a search for prospective or retrospective cohort studies.
Search limitations
Date, language and search source restrictions as stated above limit the
comprehensiveness of our search strategies.
One of the challenges of systematically searching for literature related to
palliative/end-of-life care is the breadth of the field, which encompasses a
variety of issues, specialties, conditions, symptoms, and interventions. Many of
the search concepts of interest occur in the title/abstract/index terms of studies
not related to palliative/end-of life care. In addition, literature on advanced
stages of illness does not consistently use palliative/end-of-life related index
terms, or include palliative/end-of-life related text words in the title or abstract.
As our initial searches focused on studies where index terms and/or textwords
indicated that content was or could be relevant to palliative/end-of-life care, we
also carried out supplemental searches and extensive expert interviews.
As a result of these search limitations, we may not have identified all relevant
citations.
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APPENDIX B: TOOLKITS
Diane E. Meier, MD
David E. Weissman, MD FACP
1. Toolkit: Nine-step guide to optimizing palliative care
in office practice
Goal: To assure high-quality palliative care in the outpatient
environment
Palliative care focuses on the relief of suffering and support for best possible
quality of life for patients with serious chronic illness and their families. It is
offered simultaneously with all other appropriate life-prolonging or curative
therapies. Palliative care, therefore, is not the same as hospice. Hospice is one
form of intensive palliative care, supported by Medicare (and other insurers)
and usually delivered at home, for patients with a prognosis of less than 6
months who have decided to give up curative or life-prolonging treatments.
The office setting is the optimal place to help patients maximize physical and
psychological comfort, and explore values that can direct future medical care
choices. All physicians should provide primary palliative care, and identify
resources for specialty-level palliative care for more challenging problems. The
following nine-step approach is aimed at the primary care provider (PCP) and
outlines some key issues for primary palliative care.
Step 1: Identify chronic disease patients with palliative care
needs
" Distressing pain or other physical/psychological symptoms
" Frequent hospitalizations or emergency room visits
" Weight loss
" Functional decline
" Spiritual or existential distress
" Exhausted/stressed family caregivers
Step 2: Assess and treat physical, psychological, and
spiritual symptoms using standard tools
Many excellent tools exist that can be incorporated into standard clinic chart
notes. See Resources (NPCRC) and individual sections within 4. Toolkit and
Part 2. Evidence review: Symptom assessment and management.255
70 © BMJ Publishing Group 2008
Step 3: Assess social/family system and identify at-risk
caregivers
Care of the seriously ill patient places huge demands on the family and
community. The PCP can best help by understanding the impact of the disease
on the patient’s family. See Resources (NPCRC).
Step 4: Help complete an advance care planning document
The most important task is to help the patient appoint a health care proxy or
surrogate decision maker whom they trust and who can help make medical
decisions for them in case of future loss of capacity.
A helpful practice is to have blank copies of state-sanctioned documents in the
examination room to give to patients, along with enough support (e.g., trained
office staff or patient education material) to help a patient complete the form.
See Resources (POLST and Caring Connections).
Step 5: Coordinate medical opinions from consultants
Patients need their PCP to help them understand the often conflicting informa-
tion about treatment choices and prognosis.
Step 6: Suggest and lead a patient-family meeting to
discuss goals of care
See 2. Toolkit and section on Communication.
Step 7: When possible, provide prognostic information
using ranges
See section on Prognostic accuracy and Arnold et al.256
Step 8: Make a timely referral for specialized palliative care
and/or hospice services
PCPs should familiarize themselves with regional palliative care resources and
the Medicare Hospice eligibility criteria. See Resources (NIPCR and MHB).
Step 9: Support families throughout the dying experience
and during bereavement
A fear of many patients and family members is abandonment by their physician.
Even though your patient may be receiving disease specific treatment from 1 or
more subspecialists, maintaining routine contact and providing information and
support will mitigate this fear for most patients and families.
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2. Toolkit: Ten-step guide to conducting a meeting to
establish goals of care
Goal: To assist seriously ill patients and their families with
setting priorities for care
Establishing goals of care is a critical palliative care skill for the inpatient or
outpatient setting. A successful meeting is more likely if key steps are
completed, in the correct order. A 10-step process is outlined below.
Step 1: Pre-meeting planning
+ Review medical history, available treatment options,
risks/benefits of treatments and prognostic information
+ Coordinate opinions among consultants
+ Ensure sufficient time is allocated for the meeting
+ Decide what is medically appropriate: what
tests/procedures/interventions do you believe will
improve or worsen function, longevity and quality of
life?
+ Review Advance Directives documents
+ Determine who you wish to have present from the medical team
and invite the family to bring whomever they wish to
the meeting
+ Designate one person to serve as meeting leader
+ Assess decision-making capacity: a patient must be able to:
" Understand information about diagnosis and
treatment
" Evaluate deliberate, weigh alternatives, compare
risks and benefits
" Communicate a choice verbally, in writing, or with
a nod or gesture
Step 2: Environment
Find a quiet, private room. Two RCTs support giving bad news from a seated
posture.257,258
Step 3: Introductions
Ask participants to introduce themselves and their relationship to the patient.
Step 4: Determine what the patient/family already knows
Suggested question: ’What is your understanding of your condition?’
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Step 5: Medical review
Provide a short synopsis of the medical situation and how it fits within the larger
illness trajectory (for chronic disease patients).
Step 6: Allow silence
Respond to questions and emotional reactions.
When the medical review has indicated that no further treatments are
likely to reverse the disease process, there are 2 common reactions:
1. Acceptance: Patients and families who accept that death is approaching will
typically ask, or be thinking, the following questions:
+ How much time? What will happen? What do we do now?
2. Nonacceptance: When patients or families are not ready to accept that
death is coming, common questions include:
+ How can you be sure? He was fine last week. We want a second opinion.
Step 7: Discuss prognosis and care options
Guidelines on discussing prognosis include:
" Always ask if such a discussion is desired before providing data
" Provide data using a range (e.g., a few weeks to a few months)
" Reviews recommend when giving bad news to include positive language
and present information on different outcomes259,15
" Stop and allow silence after the information is provided, to address any
emotional reaction.
Options usually break down into:
+ Continuing or expanding life-prolonging treatments with a goal of improved
function, lengthened life, and/or improved quality, OR
+ Discontinue life-prolonging treatments with a goal solely on comfort/quality.
When patients can speak for themselves
" Ask the patient what treatment he/she is considering and why
" Ask the patient what type of support he/she would like from family members
and health care team.
When patients cannot speak for themselves
" Ask each family member, or surrogate decision-maker, what they believe the
patient would choose if he/she were able to speak on his/her own behalf.
Making a recommendation
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When patients/families struggle to make a decision, or you believe there is 1
preferred medical decision based on the facts and the patient’s wishes, make a
clear recommendation.
Step 8: Managing conflict
Conflicts concerning the goals of care between family members, or between the
family/patient and the physician, are common:
+ Grief/Time: Family members have not had sufficient time to
psychologically adjust to imagining their life without
the dying person
+ Information: Incorrect, misleading, or conflicting information has
been provided to the family by other health care
providers or other sources
+ Anger/Guilt: Long-lasting intrafamily issues may disrupt or
preclude logical decision-making
+ Trust: If a patient or family does not have trust in the
medical team, it is impossible to work together to
develop a treatment plan
+ Culture: Differences in culture, religion, socioeconomic status
and so on may all impede decision-making
Key points for managing conflict
" Use good active listening skills: Strive to maintain a civil discourse
" Provide an empathic statement: ’I can’t imagine how hard this must be!’
" Correct factual misunderstanding
" Keep the discussion focused on the patient’s well-being
" Recognize that time may be necessary and schedule a follow-up meeting
" Establish a time-limited trial of continued life-sustaining treatments: Estab-
lish clear goals and a time line (e.g., improved cognition within the next 3 days)
" Recognize that other resources may help the family: psychologist, spiritual
counselor, palliative care team, ethics consultation
" State directly that you (and the health care team) will not abandon the
patient and family.
Step 9: Translate goals into a care plan
If a decision has been made to limit further life-sustaining treatments, it is time
to refocus the goals of care. Even for patients with a poor prognosis hope is
possible if they can focus on achievable goals.16
" Suggested question: ’Knowing that time is short, what is important and what
do you want or need to do in the time you have left?’
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" Review the current medical tests/ medications and decide which ones are
helping to meet the patient’s goals, which are providing no benefit.
Step 10: Document and Discuss
" Summarize the main points and reassess the patient’s understanding
" Provide concise written documentation of the meeting
" Provide contact details for further information
" Discuss the meeting with health care providers who were unable to attend.
3. Toolkit: Care coordination for early, middle and late
stages of serious chronic illness
Adapted from Morrison RS, Meier DE. Palliative care. N Engl J Med.
2004;350:2582–2590.255
Early stage
(e.g., time of diag-
nosis)
Middle stage
(e.g., progressive
disease and increas-
ing functional
decline)
Late stage
(e.g., death is immi-
nent)
Goals of
care
" Discuss
diagnosis,
prognosis, and
likely course of
illness
" Discuss/offer
disease-modifying
therapies
" Discuss
patient-centered
goals, hopes, and
expectations of
medical
treatments
" Review
understanding of
diagnoses/
prognosis
" Review
efficacy and
benefit/burden
ratio of disease
modifying
treatment
" Reassess
goals of care and
expectations;
prepare
patient/family for
shift in goals
" Encourage
completion of
important tasks,
relationships,
financial affairs
" Assess
understanding of
diagnosis, disease
course, prognosis
" Review
appropriateness of
disease-modifying
treatments
" Review goals
of care and
recommend
appropriate shifts
" Explicitly plan
for a peaceful
death
" Encourage
completion of
important tasks,
relationships,
financial affairs
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Early stage
(e.g., time of diag-
nosis)
Middle stage
(e.g., progressive
disease and increas-
ing functional
decline)
Late stage
(e.g., death is immi-
nent)
Pro-
gram-
matic
support
" Visiting nurse
and home care
services
" Case
management
services if
available
" Visiting nurse
and home care
services
" Consider
hospital/home
care; palliative
care programs;
hospice;
" Subacute
rehabilitation; case
management
services; PACE
" Hospital/home
care based
palliative care
program; hospice
" Case
management
services
" PACE
" Nursing home
placement with
hospice/palliative
care if care needs
are overwhelming
to family
Finan-
cial
planning
" Advise
financial/estate
planning,
long-term care,
insurance options
" Consider
asset transfer if
need for Medicaid
" Refer to an
elder lawyer
" Assure
financial planning
for medical, home
care, prescription,
long-term care,
and family support
needs
" Consider
hospice referral;
Medicaid eligibility
" Ask about
financial
resources/needs
" Inform
patient/family of
possibility of
Medicaid eligibility
if resources
inadequate
" Explicitly
recommend and
review advantages
of hospice
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Early stage
(e.g., time of diag-
nosis)
Middle stage
(e.g., progressive
disease and increas-
ing functional
decline)
Late stage
(e.g., death is immi-
nent)
Family
support
" Offer support
groups
" Ask about
practical needs
(transportation,
prescription drug
coverage, respite
care, personal
care)
" Listen
" Encourage
support/
counseling for
family caregivers
" Screen family
caregivers for
practical resource
needs, stress,
depression,
adequacy of
medical care,
identify respite
and practical
support resources,
recommend help
from
family/friends,
raise possibility of
hospice and its
benefits
" Listen
" Encourage
out-of-town family
to visit
" Refer to
disease-specific
support
groups/counseling
for family. Inquire
about caregiver
health, well-being,
practical needs
" Offer respite
care
" After death,
send bereavement
card and call after
1 to 2 weeks
" Screen for
high-risk
bereavement
" Maintain
occasional contact
after patient’s
death
" Listen
4. Toolkit: Pain and other symptoms
Adapted from Morrison RS, Meier DE. Palliative care. N Engl J Med.
2004;350:2582–2590.255
Anorexia/Cachexia
" Assessment: Dx disease process versus consequence of untreated
nausea, constipation, pain? Is patient troubled by the symptom?
" Treatment: Megestrol acetate or dexamethasone
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Anxiety
" Assessment: Common symptom, including restlessness, agitation,
insomnia, hyperventilation, tachycardia, excessive worry
" Treatment: Supportive counselling. Benzodiazepines (avoid
long-acting agents in elderly)
Constipation
" Assessment: Common symptom, has major adverse effects
(perforation, bowel obstruction, nausea, anorexia, pain)
" Disimpact prior to initiating oral therapy
" Treatment: Stool softener (ineffective alone) plus stimulant laxative,
titrate to effect. Add osmotic laxatives, enemas if necessary.
Depression
" Assessment: Ask “Are you depressed?”—sensitive and specific
question for dx
" Symptoms: helplessness, hopelessness, anhedonia, loss of
self-esteem, worthlessness, guilt, dysphoria, and suicidal ideation
" Suicidal ideation represents extreme distress and should be routinely
assessed
" Treatment: Cognitive/behavioral counselling. Psychostimulants
unless tachycardia or acute coronary ischemia. Selective serotonin
reuptake inhibitors may take 3 to 4 weeks to take effect. Tricyclic
antidepressants are relatively contraindicated due to their side effects.
Delirium
" Assessment: Acute change in level of consciousness, with agitation
and/or lethargy, inattention, disorientation, fluctuation, and reversibility.
Often remembered and causes significant distress to patient and family
" Treatment: Treat symptom while seeking reversible contributors.
Reduce excess stimulation, provide reorientation, reassurance, assure
presence of family if possible. Effective medications include haloperidol,
risperidone, olanzapine. Chlorpromazine can be used for agitated or
terminal delirium. Benzodiazepines exacerbate delirium and should be
avoided.
Dyspnea
" Treat reversible causes
" Treatment: Oxygen is effective with or without hypoxia via stimulation
of the V2 branch of the trigeminal nerve. Fans are helpful. Opioids reduce
breathlessness in RCTs without reductions in respiratory rate or oxygen
saturation. Effective doses are lower than those used to treat pain.
Anxiolytics: Low-dose benzodiazepines. Behavioral: Reassurance,
relaxation, distraction, breathing techniques, and massage therapy.
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Nausea
" Assessment: Multiple mechanisms (chemoreceptor trigger zone
stimulation, gastric stimulation, delayed gastric emptying/squashed
stomach, bowel obstruction, intracranial processes, and vestibular vertigo)
and neurotransmitter contributors
" Treatment: Successful treatment is based on specific cause
Vestibular: Cholinergic, histaminic receptors. Rx: Anticholinergic
(scopolamine), antihistaminic (diphenhydramine, promethazine)
Obstruction of bowel caused by constipation: Cholinergic, histaminic,
5HT3 receptors. Rx: Disimpact, myenteric plexus stimulants such as senna
Dysmotility of upper gut: Cholinergic, histaminic, 5HT3 receptors. Rx:
Prokinetics, metoclopramide
Infection, inflammation: Cholinergic, histaminic, 5HT3, neurokinin 1
receptors. Rx: Anticholinergic (scopolamine), antihistaminic
(diphenhydramine), 5HT3 antagonists (ondansetron, granisetron),
anti-inflammatory (corticosteroids).
Toxins stimulating the CTZ in the brain such as opioids: Dopamine 2,
5HT3 receptors. Rx: Antidopaminergic (haloperidol, metoclopramide),
5HT3 antagonist (ondansetron).243
Pain
" Assessment: Assess daily using numeric rating scale (0 to 10 or 0 to
3)
" Treatment: Dose analgesics standing, interval based on half-life
" PRN doses for pain not controlled by the standing regimen, dosing
interval based on time to onset
" All patients on opioids should be started on a bowel regimen
" The WHO Analgesic Ladder should be used for most pain syndromes
Mild pain: Acetaminophen or a NSAID (opioids probably safer in older
adults)
Moderate pain: Opioid combination product (acetaminphen + codeine,
acetaminophen + oxycodone, acetaminophen + hydrocodone) and dose
based upon opioid half-life (3 to 4 hours) not acetaminophen half-life (6 to
8 hours). No more than 4 g acetaminophen total per 24-hour period
Severe pain: Standing opioids (hydromorphone, morphine, oxycodone)
and titrate to relief or intolerable side effects. Long-acting opioids
(sustained release morphine/oxycodone, transdermal fentanyl) should be
started after pain is well-controlled. Methadone should only be prescribed
by clinicians experienced in its use.
Rescue doses: Short acting opioids at 10% of the 24-hour total opioid
dose at 1 hour (oral) or 30 minute (parenteral) intervals; PRN
Adjuvant agents: Corticosteroids, anticonvulsants, tricyclic
antidepressants, bisphosphonates should be employed for specific pain
syndromes when applicable.
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Resources
National Consensus Project
http://www.nationalconsensusproject.org
A national framework and preferred practices for palliative and hospice care
quality
http://216.122.138.39/publications/reports/palliative.asp
Facts on dying: Policy relevant data on care at the end of life
http://www.chcr.brown.edu/dying/usastatistics.htm
Medicare Hospice Benefits (MHB)
http://www.medicare.gov/publications/pubs/pdf/02154.pdf
The Family Goal Setting Conference Pocket Card http://www.mcw.edu/
palliativecare/pocketcards.htm
Caring Connections: End-of-life resources and state-specific living will or
healthcare power of attorney
http://www.caringinfo.org
Physician Orders for Life-Sustaining Treatment (POLST) program
http://www.ohsu.edu/polst/professionals.shtml
Hospital Elder Life Program (HELP)
http://hospitalelderlifeprogram.org
National Palliative Care Research Center (NPCRC): Resources, Measurement
and Evaluation tools
http://www.npcrc.org/resources/resources_list.htm?cat_id=1246
National Information on Palliative Care Resources (NIPCR)
www.Getpalliativecare.com
U.S. Pain Policy Resources
http://www.painpolicy.wisc.edu/states.htm
TIME: Toolkit of Instruments to Measure End-of-life Care
http://www.chcr.brown.edu/pcoc/toolkit.htm
City of Hope: Pain & Palliative Care Resource Center Website
http://www.cityofhope.org/prc/
End-of-Life/Palliative Education Resource Center
http://www.eperc.mcw.edu
Center to Advance Palliative Care
http://www.capc.org
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